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ABSTRACT 
TREATMENT OF DUAL DIAGNOSIS POST TRAUMATIC STRESS DISORDER 
AND SUBSTANCE USE DISORDERS: A META-ANALYSIS 
 
 
Joshua Dolan 
 
Marquette University 
 
 
The dual diagnosis of post-traumatic stress disorder and substance use disorders 
affects a large number of people. Various treatments have been used for addressing these 
co-occurring disorders and have now been empirically tested. These treatments can be 
divided into two categories: sequential and integrated. The goal of this study was to meta-
analytically examine the effectiveness of these treatments and compare these two 
categories of treatment. Secondary objectives included the exploration of potential 
moderator variables and the symptom interplay between the two disorders after treatment. 
The results of the study suggested that treatment for the dual diagnosis of post-
traumatic stress disorder and substance use disorders is generally effective. There were 
no major differences, however, between the two categories of treatment. There also was 
no evidence of symptom interplay. There were no clear moderators. There was also 
evidence that outcomes in this area of the research literature are being affected by the 
“file drawer” problem, though likely not to a degree that would greatly weaken these 
results. 
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CHAPTER I 
OVERVIEW 
 Post-Traumatic Stress Disorder (PTSD) and Substance Use Disorders (SUD) each 
involve symptoms that can be quite debilitating (American Psychological Association, 
2000). Individually, each of these disorders affects a large number of people, and a large 
number of people are affected by the combination of the disorders occurring 
simultaneously (American Psychological Association, 2000; National Center for PTSD, 
2008; Substance Abuse and Mental Health Services Administration, 2006). When they do 
occur together, the resulting syndrome can be very difficult for afflicted individuals to 
cope with and for health care providers to treat. 
To gain a full understanding of what the dual diagnosis looks like, one needs to 
have a basic understanding of the presentation of each disorder alone. The Diagnostic and 
Statistical Manual of Mental Disorders IV-Text Revision (DSM-IV-TR) (American 
Psychiatric Association, 2000) describes PTSD as a set of symptoms that arise after an 
individual experiences some kind of traumatic event such as injury or threat to self or 
witnessing such an event toward another. This event must be responded to with fear, 
helplessness, or horror. This event then leads to three symptom clusters: re-experiencing 
the event, avoidance of event stimuli, and increased arousal. Re-experiencing the event 
includes nightmares, flashbacks, dissociation, or intrusive thoughts. Avoiding stimuli 
regarding the events refers to the individual’s attempts to avoid things that would remind 
her or him of the event itself and which can lead to avoidance of particular people, places, 
thoughts, or activities. The third symptom cluster, increased arousal, includes difficulty in 
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falling asleep, hypervigilance, exaggerated startle reflex, or increased anger and 
irritability. 
PTSD is estimated to occur in about 8% of the United States population at some 
point in their lives (American Psychiatric Association, 2000; National Center for PTSD, 
2008). The National Center for PTSD (2008) further estimates that about 10% of women 
and 5% of men can be diagnosed with PTSD in their lives. In terms of traumatic events, 
this study estimated that about 60% of men report at least one traumatic event in their 
lives while about 50% of women report the same.  
For the purposes of this dissertation, SUD will be defined as either substance 
abuse or dependence as described by the DSM-IV-TR (American Psychiatric 
Association, 2000). The DSM-IV-TR defines substance abuse as a pattern of substance 
use that leads to physically hazardous situations, legal or social problems, and a failure to 
fulfill life responsibilities (i.e., work or family). Substance dependence is the more severe 
disorder and includes tolerance effects, withdrawal, more substance use than intended, 
failures to quit, a large amount of time spent in substance use activities, decrease in other 
activities, and continued use despite the aforementioned problems. While the DSM-IV-
TR includes many different classes of substances within these categories, this review will 
focus solely on alcohol and illegal drugs.  
It is estimated that approximately 15% of the population meets the diagnostic 
criteria for alcohol dependence sometime during their lifetimes (American Psychiatric 
Association, 2000). Estimates for the lifetime prevalence for various illegal drugs are 
1.5% for amphetamines, 5% for cannabis, 2% for cocaine, 0.6% for hallucinogens, and 
0.7% for opioids (APA, 2000). It is estimated that twenty-two and a half million 
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Americans (8.9% of the population twelve years of age and older) meet the criteria for a 
SUD every year (Substance Abuse and Mental Health Services Administration, 2010). 
There have been a wide range of prevalence estimates for the dual diagnosis of 
SUD and PTSD. These estimates have ranged from 10.9% (Najavits, Runkel, et al., 2003) 
to 41% (Brown, Read, & Kahler, 2003) for SUD treatment samples having comorbid 
PTSD. More recent estimates have found 22.4% of individuals with cocaine dependence 
and in treatment also had PTSD (Afful, Strickland, Cottler, & Bierut, 2010). Similar rates 
have also been found across cultures with 25.3% of a German SUD treatment seeking 
sample also having co-occurring PTSD (Driessen et al., 2008). One study examining 
individuals in a PTSD treatment program found that 91.2% of the participants also had a 
lifetime SUD diagnosis (Boudewyns, Woods, Hyer, & Albrecht, 1991). However, there is 
reason to believe that participants of this last study had much more severe PTSD than 
usual. Most of the other studies found comorbidity rates between 25% and 30%. These 
rates seemed to hold across different age groups and countries. The highest prevalence 
rate was found in a study of lower socioeconomic status (SES) inner-city women with 
59% of the participants experiencing both SUD and PTSD (Fullilove et al., 1993), 
suggesting that SES may play a role in the incidence of the comorbid syndrome. Given 
the high rates of comorbid PTSD and SUD found across samples, some authors have 
suggested that co-occurring disorders should be viewed as an expectation in the substance 
abusing population (Minkoff & Cline, 2004). With these high rates, it is imperative that 
effective treatments are found and utilized with this population. 
Most studies of treatment outcomes for dual PTSD AND SUD individuals have 
found that individuals with the dual diagnosis have worse outcomes than individuals with 
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either disorder alone (Trafton, Minkel, & Humphreys, 2006). Mills, Teesson, Ross, and 
Darke (2007) found mixed results where individuals with dual diagnoses improved more 
on some measures but did worse on others. Brown, Stout, and Mueller (1996) found that 
women with comorbid PTSD in an inpatient substance abuse treatment facility relapsed 
faster after treatment then women in the same facility without PTSD. Surveys of 
clinicians have found that they believe that the dual diagnosis is more difficult to work 
with than either disorder alone (Najavits, 2002a). An early review of dual PTSD and 
SUD suggested that the reasons that this dual diagnosis is difficult to treat are the 
difficulty in assessment due to the amorphous nature of PTSD and that these individuals 
have a tendency to isolate, have survivor guilt, suffer from depression, and have a great 
deal of rage (Jelinek & Williams, 1984). 
Furthermore, it appears that these individuals are not receiving the more 
specialized treatment that they need. In a survey of women with dual PTSD and SUD, 
Najavits, Sullivan, Schmitz, Weiss, and Lee (2004) found that the most utilized past 
treatments in this population were individual psychotherapy, psychopharmacological 
treatments, inpatient hospitalization, group psychotherapy, and SUD counseling. Only 
about half of the participants were receiving treatment for both PTSD and SUD. 
Chiavaroli (1992) examined the treatment files of individuals with a sexual abuse history 
who were in a substance abuse treatment facility and found that their trauma was rarely 
addressed. 
Clients themselves report emotional pain, shame, and guilt as being the barriers to 
getting treatment (Brown, Stout, & Gannon-Rowley, 1998). In a survey of clinicians 
regarding difficulties surrounding treatment of this dual diagnosis, the clinicians reported 
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clients’ self-destructiveness, case management needs, and dependency as the highest 
ranked difficulties (Najavits, 2002a). 
Statement of Problem 
 Considering the scope and nature of the PTSD and SUD dual diagnosis, it is 
important that effective treatments be found. Up to this point, various treatment models 
have been proposed and empirically tested for this dual diagnosis. However, a search of 
the literature found no study that combined and compared these studies through meta-
analysis. A number of isolated studies have been conducted on the interplay of the 
symptoms in these two disorders, but there has not been a quantitative integration of 
these studies. 
Purpose 
The purpose of this dissertation is to quantitatively examine the literature using a 
meta-analytic approach to determine the effectiveness of treatment for the PTSD and 
SUD dual diagnosis. Currently there is a movement toward integrated treatments for this 
dual diagnosis, but there is as yet no examination regarding whether or not these 
integrated treatments are any more effective than treatments aimed at either the PTSD or 
SUD individually.  Therefore, this study compared the effectiveness of integrated PTSD 
and SUD treatments versus non-integrated treatments. 
 A secondary purpose was to explore the symptom interplay between the disorders 
to determine how they affect each other throughout treatment and recovery. There are 
numerous theories addressing how the different symptomologies affect one another, but 
no empirical examination of this question has yet been conducted. Therefore, this study 
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examined treatment follow-up data to compare PTSD and SUD symptoms over time to 
determine if and how they interact. 
Research Questions 
1) What is the effectiveness of treatment for individuals with the dual diagnosis of 
PTSD and SUD as measured by PTSD, SUD, and other psychological symptoms 
between pre- and post-treatment? 
2) Are there differences in the effectiveness of treatments between sequential and 
integrated treatments for individuals with dual diagnosis PTSD and SUD? 
3) Are there moderating influences on treatment outcomes for PTSD and SUD dual 
diagnosis? 
4) How do PTSD and SUD symptoms progress over time after treatment as 
measured by symptom change scores at post-treatment and follow-up 
measurements? 
A meta-analytic technique was employed to answer these questions. The primary 
procedure used was Hunter and Schmidt’s (2004) technique for meta-analysis and 
correction. This procedure uses effect size data attained from individual studies and 
statistically corrects for systematic errors and biases that may be occurring to attempt to 
attain as accurate a view as possible of the true population effect size scores.  
All meta-analyses are contingent upon the literature on which they are based. The 
literature on dual diagnosis PTSD and SUD is still a relatively new one that is also 
limited in size. As long as the literature base is sufficiently large, however, meta-analysis 
can be quite useful for providing preliminary answers to the aforementioned research 
questions. 
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Definition of Terms 
Particularly relevant terms used in this document are defined as follows. 
Coding: Process of converting study information into useful meta-analytical data 
(Stock, 1994). 
Correction: Process of correcting for the various statistical and methodological 
artifacts that have biased individual study effect sizes (Hunter & Schmidt, 2004). 
Dual diagnosis: Diagnosis of two or more mental disorders within a single 
individual (APA, 2000). 
Integrated (or concurrent) treatments: Treatments for a dual diagnosis that treat 
both diagnoses simultaneously (Back, Waldrop, Brady, & Hien, 2006). 
Meta-analysis: Technique by which data from multiple independent sources can 
be synthesized into a useful form (Hunter & Schmidt, 2004). 
Moderator variable: Variable that may be causing variation in the results of an 
analysis (Hunter & Schmidt, 2004). 
Sequential treatments: Treatments for a dual diagnosis that focuses on a single 
diagnosis first, before treating the second diagnosis (Back, Waldrop, Brady, & Hien, 
2006). 
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CHAPTER II 
LITERATURE REVIEW 
A discussion on the dual diagnosis of PTSD and SUD can be divided into two 
main sections. The first of these sections examines diagnostic issues that include etiology, 
maintenance, and presentation of the dual diagnosis. The second section will summarize 
the treatment literature for dual SUD and PTSD.  
Diagnostic Issues 
 Diagnostic issues regarding dual PTSD and SUD encompass the areas of etiology, 
maintenance, and presentation. Knowledge of the development of dual diagnosis PTSD 
and SUD can help inform the treatment of individuals with this comorbidity. For 
example, if one of the disorders develops first and seems to underlie the other, then 
treating that underlying disorder would become the primary therapeutic priority. Once 
both disorders develop there are a variety of ideas on how they maintain each other. 
Many of these theories describe a cyclical pattern in which symptoms of one disorder 
lead to an increase in symptoms of the other. Information on maintenance can also help 
inform and explain the behavioral patterns that are seen with this population. 
Furthermore, once the comorbidity is established, it cannot be assumed that the client’s 
symptomology is simply the two disorders’ symptomologies added together as they may 
combine to form a syndrome whose total is greater than the sum of its parts and is 
especially intractable and resistant to change. Thus, all three of these areas of etiology, 
maintenance, and presentation can help inform treatment decisions. 
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Etiology 
There are a variety of theories on how the dual diagnosis develops. Some of these 
theories state that one disorder causes the other, while others discuss some third variable, 
such as genetics or some other factor, that serves as a vulnerability for both disorders. 
Examples of factors that have been statistically significantly implicated in the 
development of dual PTSD and SUD are low levels of education, high number of traumas 
experienced, high perception of threat to life, and low social support (Ullman, Filipas, 
Townsend, & Starzynski, 2006). Sociological factors such as culture, family environment 
and poverty may also serve as vulnerabilities (Logan, Walker, Cole, & Leukefeld, 2002).  
Research has identified the psychological factor of low self-regulatory ability as a 
major vulnerability factor for the development of PTSD and SUD dual diagnosis (Hien, 
Cohen, & Campbell, 2005; Khantzian, 1997). A similar construct, coping skills, has also 
been suggested as a vulnerability (Simpson, Jakupcak, & Luterek, 2006; Ullman, Filipas, 
Townsend, & Starzynski, 2005). These findings support the viewpoint that both disorders 
are unhealthy ways of dealing with stressful life events. 
Genetics and early family environment have also been suggested as potential third 
variables. A study by Dierker and Merikangas (2001) found that a family history of SUD 
increased the risk for PTSD by nearly four times. Xian et al. (2000) examined 3,000 twin 
pairs who were male Vietnam War veterans and found that PTSD and SUD shared 
additive genetic components as well as contributed distinct components accounting for 
about 25% of the variance of the disorders.  
The type of trauma that underlies the diagnosis of PTSD may also serve as a 
vulnerability, as more severe forms of trauma significantly increase dual PTSD and SUD 
Treatment of Dual Diagnosis 10 
 
 
rates (Stewart, Mitchell, Wright, & Loba, 2004). These more severe forms of trauma 
involve assaults by non-strangers, combat trauma, childhood trauma, and life threatening 
illnesses (Brinson & Treanor, 1989; Dragan & Lis-Turlejska, 2007; Raghavan & 
Kingston, 2006; Waldrop, Santa Ana, Saladin, McRae, & Brady, 2007). Stewart, 
Mitchell, et al. (2004) found that individuals with PTSD were statistically significantly 
more likely to use substances to cope following more severe traumas.  
Another important question is if one disorder causes the other. Does SUD cause 
PTSD or is it the other way around? Research has examined the temporal order of the 
disorders, but the results are inconclusive with some studies finding that SUD tends to 
precede PTSD (Kilpatrick, Ruggiero, et al., 2003; Cottler et al., 1992) while others 
finding PTSD precedes SUD (Shipherd, Stafford, & Tanner, 2005; Mills, Teesson, Ross, 
& Peters, 2006; Reed, Anthony, & Breslau, 2007; Chilcoat & Breslau, 1998). Some 
neuropsychological studies suggest that stress and trauma can produce changes in the 
brain that place an individual at greater risk for SUD (Goeders, 2003). Gender has also 
been identified as a possible moderating variable that affects which disorder precedes the 
other (Deykin & Buka, 1997; Jaycox, Ebener, Damesek, & Becker, 2004). 
Many of these etiological studies that examined which disorder preceded the other 
utilized large sample sizes, but the retrospective nature of these studies resulted in 
findings susceptible to recall bias. Only a few utilized longitudinal designs (e.g. Shipherd 
et al., 2005) that would not be susceptible to this type of bias. Furthermore, many utilized 
measures of unknown (or unreported) psychometric quality, which weakened the 
reliability of the results. 
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Maintenance  
Several proposals have been offered regarding how these two disorders maintain 
each once they develop. Many of these proposals describe a cyclical pattern in which 
symptoms of one disorder lead to an increase in the other disorder (Clark, Masson, 
Delucchi, Hall, & Sees, 2001; Stewart & Conrod, 2003). The participants of a study of 
combat experienced Vietnam veterans reported that the symptoms of both PTSD and 
SUD increased simultaneously after the war (Bremmer, Southwick, Darnell, & Charney, 
1996). A 20-year study of Vietnam veterans (Price, Risk, Haden, Lewis, & Spitznagel, 
2004) found SUD appeared to exacerbate PTSD initially but as time went on the PTSD 
appeared to lead to continuation of the SUD. Individuals with PTSD and SUD have also 
reported that they believe that the symptoms of the two disorders are related to one 
another (Brown, Stout, & Gannon-Rowley, 1998; Reynolds et al., 2005).  
These findings suggest that once the dual disorder develops, each of the 
components serves to maintain the other in some form of a positive feedback loop. 
Potential processes by which the disorders may maintain each other include SUD 
symptoms exacerbating and prolonging PTSD by preventing habituation to trauma, SUD 
withdrawal symptoms being misinterpreted as PTSD symptoms, and SUD symptoms 
retriggering PTSD symptoms through mechanisms such as sleep disturbances (Stewart, 
Pihl, Conrod, & Dongier, 1998). This cycle can also occur through automatic processes 
such as cue reactivity or other neurological processes (Cohen, Mannarino, Zhitova, & 
Capone, 2003; Conrod & Stewart, 2003).  
A theory used to describe how PTSD can lead to SUD symptoms is Khantzian’s 
(1985; 1997) self-medication hypothesis. This hypothesis states that individuals use 
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specific substances to self-medicate uncomfortable feelings or thoughts and alleviate 
suffering. Stewart (1996) stated that binge drinking is triggered by increases in PTSD 
symptoms because alcohol reduces tension, dampens physiological stress reactions, 
reduces negative mood states and alexthymia, and reduces the intrusive symptoms of 
PTSD. A factor analysis of PTSD found correlates with specific substances (Stewart, 
Conrod, Pihl, & Dongier, 1999). Alcohol was found to be associated with arousal 
symptoms, anxiolytics with arousal and numbing symptoms, and analgesics with arousal, 
intrusions, and numbing symptoms. Jacobsen, Southwick, and Kosten (2001) stated that 
depressants may cause arousal symptoms similar to those of PTSD.  
A study of substance use relapse factors found that PTSD symptoms predicted 
relapse in negative interpersonal, negative physiological, and social pressure situations 
(Norman, Tate, Anderson, & Brown, 2007). Waldrop, Back, Verduin, and Brady (2007) 
also found that individuals with dual diagnosis PTSD AND SUD were more likely to use 
substances in negative situations such as the experience of negative emotions or physical 
discomfort. One mixed methods study (Condon, 2004) interviewed ten individuals with 
dual PTSD and SUD and found that the participants reported using substances to numb 
feelings and forget negative memories.  
The arousal symptom cluster of PTSD in particular seems to have the most effect 
in maintaining SUD (Ouimette, Moos, & Brown, 2003; Stewart, Pihl, et al., 1998). 
Alcohol abuse may increase arousal in individuals so that they are more likely to develop 
and maintain PTSD (Stewart, 1996). Another study found that while all the PTSD 
symptoms tended to decrease with time in participants who were assaulted in the 
previous month, the arousal symptoms in those with alcohol use problems deceased less 
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(Kaysen, Simpson, et al., 2006). In contrast, another study (Kaysen, Simpson, et al., 
2006) assessing women who had been assaulted in the previous month found that alcohol 
use predicted intrusion and avoidance symptoms but not arousal symptoms after the 
trauma. 
Najavits, Runkel, et al. (2003) found that the arousal symptom set of PTSD was 
most prominent in a sample of individuals with cocaine dependence and PTSD, which is 
consistent with the stimulative properties of cocaine. Stewart, Mitchell, Wright, and Loba 
(2004) found elevated hyper arousal and re-experiencing symptoms. Brown (2000) found 
that the re-experiencing cluster of PTSD predicted future SUD and PTSD outcomes in 29 
women who were in a non-PTSD focused multimodal treatment. Van Der kolk, 
Greenburg, Boyd, and Krystal (1985) state that opiates have similar withdrawal 
symptoms as the arousal symptoms of PTSD.  
Brown, Read, and Kahler (2003) found that individuals in SUD treatment who 
maintained their PTSD diagnosis from baseline to a 6-month follow-up had worse 
substance use outcomes then those who remitted or those who did not have PTSD. The 
individuals who experienced unremitted PTSD maintained their greater reliance on 
negative coping styles while those who showed improvement had less negative coping 
style reliance. In a re-examination of Brown, Read and Kahler’s (2003) data, Ouimette, 
Coolhart, Funderburk, Wade, and Brown (2007) calculated odds ratios for relapse. 
Participants with unremitted PTSD were 7.38 times more likely to use due to depression 
then those participants without PTSD. Participants with PTSD were also statistically 
significantly more likely to spend a lot of effort to get the substance, have more urges to 
use, were more than three times more likely to think about using before the actual use and 
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more than three times more likely to use to intoxication than those without PTSD. These 
individuals with PTSD were also less likely to have confidence in their ability to avoid 
relapse and use due to interpersonal pressures.  
It appears that many factors interact with each other to maintain the dual 
diagnosis. Each disorder is likely to maintain the other either directly and/or indirectly 
through other factors. Gil-Rivas, Fiorentine, and Anglin (1996) found that while PTSD 
was not associated directly with relapse, it was associated with a variety of factors such 
as depression, self-esteem, and anxiety, all of which were correlated with relapse.  
Presentation 
 Individuals with PTSD and SUD dual diagnosis present to treatment with a 
variety of symptoms, some of which are a result of the individual disorders while others 
result from the dual combination (Schafer & Najavits, 2007). These symptoms span the 
biological, psychological and social domains of functioning.  
Biological. The dual diagnosis of SUD and PTSD can have a large impact on 
brain functioning. Some authors hypothesize that the dual diagnosis of PTSD and SUD 
leads to impairments in executive functioning and memory, under-reactivity to visual 
affective stimuli (due to PTSD numbing), and over-reactivity to trauma/drug related cues,  
(Samuelson, et al., 2006; Sokhadze, et al., 2007). Other reviews (Brady & Sinha, 2005) 
suggest that the HPA axis, extra-hypothalamic cortico-releasing factor (CRF), and the 
noradrenergic system are all involved in this dual diagnosis. Increased levels of CRF may 
enhance the addictive nature of some drugs and increase PTSD symptoms such as the 
arousal set of symptoms. Brady, Waldrop et al. (2006) found that participants with the 
Treatment of Dual Diagnosis 15 
 
 
dual diagnosis experienced a neurological numbing but at the same time a subjective 
heightening of stress reactions. 
Individuals with dual PTSD and SUD also tend to have worse health outcomes 
(Tate, Norman, McQuaid, & Brown, 2007; Mills, Teesson, Ross, & Peters, 2006; Brown, 
Recupero, & Stout, 1995; Lester, 2007; Mills, Lynskey, Teesson, Ross, & Darke, 2005; 
Kaysen, Pantalone et al., 2008; Peirce, Kindbom, Waesche, Yuscavage, & Brooner, 
2008). Ouimette, Goodwin, and Brown (2006) found that those with SUD and PTSD self-
reported more cardiovascular and neurological symptoms, as well as more chronic 
physical symptoms than those with SUD only. A study (Waldrop, Back, Sensenig, & 
Brady, 2008) examining the effects of PTSD and alcohol dependence on sleep found that 
participants with PTSD and alcohol dependence had worse sleep quality (i.e. daytime 
sleepiness or mid-sleep awakening) than participants without these disorders.  
Brown, Stout, and Mueller (1999) calculated that individuals with dual PTSD and 
SUD incurred $4,042 in inpatient addiction services while SUD-only individuals incurred 
$780 during the same time period. Mills, Teesson, Ross, Darke, and Shanahan (2005) 
also found that dual diagnosis trended toward more costs but not in a statistically 
significant manner. 
Psychological. Individuals with the dual diagnosis of PTSD and SUD are more 
prone to other mental health disorders (Kovach, 1986; Lester, 2007; Peirce et al., 2008; 
Brown, Stout, & Mueller, 1999; Read, Brown, & Kahler, 2004). Other studies have found 
that those with SUD and PTSD have worse mental health functioning than those with 
SUD only or those with no diagnosis (Mills, Lynskey, et al., 2005; Najavits, Harned, et 
al., 2007; Ouimette, Goodwin, and Brown 2006; Trafton, Minkel, & Humphreys, 2006; 
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Ullman, Townsend, Starzynski, Long, 2006) though Najavits, Weiss, and Shaw (1999) 
did not find greater psychological symptoms among dual diagnosis women versus 
women with PTSD only. Individuals with this dual diagnosis were more likely to use 
multiple classes of drugs (Dragan & Lis-Turlejska, 2007; Mills, Lynskey, et al., 2005; 
Peirce et al., 2008; Rotunda, O'Farrell, Murphy, & Babey, 2008) and have longer drug 
use histories (Read, Brown, & Kahler, 2004; Trafton, Minkel, & Humphreys, 2006). 
Other psychological processes also affected by this dual diagnosis. Individuals 
with this dual diagnosis tend to have greater rates of suicidal ideation (Price et al., 2004; 
Harvey, Rawson, & Obert, 1994) and attempts (Najavits, Weiss, & Shaw, 1999) than 
individuals with either diagnosis alone. On measures of cognitive distortions, women 
with dual PTSD and SUD scored higher than a PTSD only group (Najavits, Gotthardt, 
Weiss, & Epstein, 2004). Najavits, Weiss, and Shaw (1999) found that women with dual 
diagnosis PTSD and SUD were statistically significantly less resilient, while Ouimette, 
Ahrens, Moos, and Finney (1998) found that individuals with dual diagnoses had lower 
coping abilities than individuals with single diagnoses. Jaycox et al. (2004) found that 
individuals with PTSD had statistically significantly more internalizing symptoms than 
individuals with SUD or SUD with a history of trauma.  
 Social. Najavits, Harned et al. (2007) found that individuals with dual diagnosis 
PTSD and SUD had statistically significantly more interpersonal problems than those 
with SUD only. These interpersonal problems included difficulties with employment 
(Peirce et al., 2008; Mills, Teesson, Ross, Darke, & Shanahan, 2005). Dual diagnosis 
individuals have been found to have statistically significantly less education and income 
than those with single SUD or PTSD (Riggs, Rukstalis, Volpicelli, Kalmanson, & Foa, 
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2003; Ullman, Townsend, et al., 2006). Adolescents with co-occurring disorders had 
more negative scores on measures of externalizing behaviors, arrests, and grade point 
averages (Kilpatrick, Ruggiero, et al. 2003). 
Riggs et al. (2003) found that individuals with this dual diagnosis were 
statistically significantly less likely to be living with a partner then single diagnosed 
individuals. These individuals have also been found to have high rates of intimacy and 
sexuality issues (Levan, 2006). Women with dual PTSD and SUD have also reported 
high rates of domestic violence (both physical and psychological) directed at them as 
well as committed by them (Najavits, Sonn, Walsh, & Weiss, 2004; Parrott, Drobes, 
Saladin, Coffey, & Dansky, 2003). In a study of aggression, the arousal symptoms of 
PTSD were positively associated with aggression both directly as well as indirectly 
through the effects of alcohol (Taft et al., 2007). Zoricic, Buljan, Thaller, and Karlovic 
(2003) found that a group with PTSD and alcohol dependence displayed statistically 
significantly more verbal and physical aggression than a group with just PTSD in a 
sample of Croatian war veterans. 
Summary 
There are a variety of theories on how this dual diagnosis develops. A great deal 
of research has been done examining various underlying factors such as genetics or a lack 
of coping skills (Dierker & Merikangas, 2001; Simpson, Jakupcak, & Luterek, 2006). It 
is also not yet clear if one disorder tends to precede the other though gender may be a 
moderating variable on the temporal development of the disorders (Jaycox et al., 2004). 
Studies that include multiple underlying factors should be used to determine which ones 
best explain the development of the dual diagnosis.  
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Once the dual disorder develops, the symptoms of one disorder appear to increase 
the symptoms of the other. While a few hypotheses have been explored on how SUD 
affects PTSD, more research has been done on how PTSD drives SUD. The most 
prominent of these latter theories is the self-medication hypothesis (Khantzian, 1997). 
Other studies have explored how specific symptom clusters are related to substance use, 
though it is still not clear how these symptom clusters interact with each other or with the 
substance abuse. It is also possible that the disorders interact through some other third 
variable such as depression. 
The dual diagnosis of PTSD and SUD represents a large cluster of potential 
symptoms. Furthermore, it has been found to have many profound effects on other areas 
of life functioning. Neurological studies have found changes in brain functioning 
associated with this dual diagnosis (Brady & Sinha, 2005). These individuals are also 
more prone to other physical and mental health issues (Tate et al., 2007; Brown, Stout, & 
Mueller, 1999), and are more likely to have interpersonal issues (Riggs et al., 2003). 
Research suggests that different individuals may develop the dual diagnosis 
through different pathways and for different reasons. Once they have the dual disorder, it 
perpetuates itself in a way that makes it difficult to treat. Unfortunately, the mechanisms 
by which it develops and is maintained are not altogether clear. Furthermore, while a 
great deal of research has been done on these mechanisms, the research is not to the point 
that it can be clinically useful for more than broad generalizations.  
Treatment 
Many different treatment models have been proposed and tested to help clients 
and therapists treat co-occurring PTSD and SUD. Some of these treatments were 
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designed for treating PTSD or SUD individually and were subsequently used with 
individuals with dual diagnoses. Other treatments were designed specifically to treat the 
dual diagnosis. These later treatments integrate components that are believed to be 
effective for both disorders. Various researchers have described the need for these 
integrated treatments (Drake, Mercer-McFadden, Mueser, McHugo, & Bond, 1998; 
Minkoff & Cline, 2004). Back, Waldrop, Brady, and Hien (2006) noted that treatments 
for dual diagnoses can be divided into two categories: sequential and integrated. The 
following sections will review both of these treatments in turn.  
Sequential Treatments 
Sequential treatments initially focus on only one of the diagnoses. Some of these 
treatments focused on SUD as a primary diagnosis and used treatments such as 12-step or 
relapse prevention models for SUD (Ouimette, Humphreys, et al., 2001). Other 
treatments have focused on PTSD as a primary diagnosis and utilized treatments such as 
exposure treatment. In one of the first articles offering suggestions for the treatment of 
this dual diagnosis, Jelinek and Williams (1984) suggested that after a thorough 
assessment is done, the client should be placed in the treatment that matches her or his 
primary diagnosis. The subsequent sections will examine the results of these sequential 
treatments.  
SUD Treatment. Treatments for SUD have a long established history. Models for 
recovery range from the Minnesota model (Anderson, McGovern, & DuPont, 1999) to 
cognitive-behavior models such as Marlatt’s Relapse Prevention Model (Witkiewitz & 
Marlatt, 2004). Many of these treatments have also been empirically tested with dual 
diagnosis clients. Other treatments like motivational interviewing have been suggested as 
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helpful but have not been empirically tested to demonstrate their usefulness with this dual 
disorder (Feldstein & Ginsburg, 2006). 
A study dealing with 12-step meeting participation and how that relates to 
treatment outcomes for individuals with dual PTSD and SUD found that individuals with 
this dual diagnosis were just as likely to attend Alcoholics Anonymous meetings as those 
individuals with SUD only (Ouimette, Humphreys, et al., 2001). Attending these 
meetings was associated with statistically significantly greater abstinence (r=.28), less 
distress (r=.27), and better quality of social relationships (r=.38) at a one-year follow-up. 
Ouimette, Ahrens, Moos, and Finney (1998) examined data from a variety of VA 
hospitals that offered treatments based on both cognitive behavioral (CBT) and 12-step 
models for SUD but no treatments aimed specifically at PTSD. Substance abuse 
counseling, family counseling, and 12-step involvement were associated with lower 
psychological symptoms among the individuals with dual PTSD and SUD at discharge. A 
one-year follow-up with these individuals found treatment gains were maintained with 
SUD outcomes but not for outcomes of psychological symptoms, employment, coping, 
and use expectancy measures (Ouimette, Ahrens, Moos, & Finney, 1997). The SUD 
outcomes were also maintained at a two-year follow-up (Ouimette, Finney, & Moos, 
1999).  
A study of CBT treatment for SUD found that in a group of individuals with dual 
PTSD and SUD, nearly 80% of the participants showed improvement for at least one of 
their diagnoses, with close to half showing improvement on both (Back, Brady, Sonne, & 
Verduin, 2006). An examination of the process of improvement during this study showed 
that alcohol symptoms decreased before PTSD symptoms, though the PTSD symptoms 
Treatment of Dual Diagnosis 21 
 
 
were assessed less regularly, which weakens this particular result. Furthermore, reduction 
in PTSD symptoms (mainly the arousal symptoms) was associated with lower drinking 
rates, but not the other way around, which the authors interpreted as meaning that PTSD 
symptoms mediate the SUD.   
Behavioral couples therapy (BCT) has also been suggested as a possible therapy 
for individuals with this dual diagnosis and their partners (Rotunda et al., 2008). Male 
veterans with PTSD and SUD were demographically matched with 19 other veterans who 
did not have PTSD. Both groups attended BCT treatment. The results showed gains for 
all of the individuals involved in BCT on drinking (r=.63), relationship (r=.30), and 
psychological distress outcomes (r=.33), but with no statistically significant differences 
between the groups. Unfortunately, improvements in PTSD outcomes were not reported. 
Najavits, Harned, et al. (2007) examined the outcomes among a group of 
individuals with cocaine dependence only and a group with cocaine dependence and 
PTSD. Participants were recruited from a variety of outpatient treatment modalities that 
used manualized SUD treatment: individual cognitive therapy, individual supportive-
expressive therapy, psychodynamic treatment, individual 12-step drug counseling, and 
group 12-step drug counseling. The PTSD group displayed statistically significant 
improved scores in global psychological symptoms, but not in addiction or interpersonal 
functioning. However, this may have been due to the PTSD group’s more severe global 
psychological symptom scores at intake. Overall, the study suggested that dual diagnosis 
clients begin treatment with greater symptomatology and do not show as much 
improvement.  
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A dissertation (Lester, 2007) based on data from a larger study examined the 
effects of contingency management versus contingency management plus day treatment 
on individuals that were homeless and had cocaine dependence. This study found that 
while the group with co-occurring PTSD was not statistically significantly different in 
number of weeks abstinent or in relapse rates, they did relapse sooner after treatment on 
average than the non-PTSD group. Individuals with the dual diagnosis in the day 
treatment program showed improvements on PTSD symptoms over those in the 
contingency management group, however improvements in PTSD symptoms were not 
associated with improvements in SUD outcomes. 
Coffey, Schumacher, Brady, and Cotton (2007) studied how PTSD and SUD 
symptoms remit over a month long abstinence during SUD treatment (which was not 
described in the study). PTSD symptomology was found to decrease for the first two 
weeks but then level off, with a trend toward increasing but not at a statistically 
significantly level. Unfortunately, even after the leveling off, PTSD was still occurring at 
clinically significant levels. 
Most of these studies suggested that SUD treatment has a positive effect on this 
dual diagnosis. Unfortunately, many of the studies did not provide treatment adherence 
data. Furthermore, there was rarely any control over potential outside treatments. These 
weaknesses make it difficult to pinpoint the cause of the outcomes with certainty. 
Diagnosis was also an issue as some articles only used chart review as a basis for 
diagnosis. 
PTSD Treatment. There have been a variety of treatments that have been shown to 
be effective with PTSD (Adshead, 2000). Most of these treatments are exposure based 
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therapies as well as interventions that attempt to teach the client coping skills or to help 
the client find meaning in life. Exposure based treatments are the premiere therapies for 
PTSD and entail some kind of reprocessing of the trauma (Powers, Halpern, Ferenschak, 
Gillihan, & Foa, 2010). Traditionally, these exposure based treatments for the dual 
diagnosis of PTSD and SUD were typically discouraged, as they were believed to 
potentially increase chances of relapse.  
A study (Coffey, Stasiewicz, Hughes, & Brimo, 2006) examining whether 
exposure therapy would lower subjective ratings of craving and negative affect used a 
sample of 43 individuals with dual PTSD and alcohol dependence randomly assigned to 
either a relaxation treatment or imaginal exposure treatment. The results showed a 
statistically significant decrease in measurements of craving and negative affect for those 
who were in the exposure group as opposed to the relaxation group, with very high 
correlation values (r = .89 and .94 for craving and subjective discomfort) between the two 
groups. The exposure group also had lower PTSD symptoms after the imaginal exposure 
treatment (r=.62) than the relaxation group. While only 50% of the participants 
completed the exposure treatment, there was no statistically significant difference 
between the groups on attrition. A reanalysis of the treatment attrition group found that 
negative affect, PTSD severity, alcohol craving, study condition (imaginal exposure vs. 
relaxation), and cocaine dependence were not associated with greater treatment drop-out 
rates, though higher negative affect trended toward statistical significance (Hughes, 
2007).  
Ouimette, Moos, and Finney (2003) provided further evidence for the efficacy of 
PTSD treatment on long-term SUD outcomes. The authors examined 118 individuals 
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who had PTSD and SUD and who had completed various types of treatment at the VA. 
These individuals were assessed through five years after treatment. The results showed 
that participants had much higher abstinence rates after PTSD treatment than with SUD 
treatment. These greater effects were especially pronounced during the first year after 
treatment, though were maintained during the entire five year follow-up. 
Integrated Treatments 
Drake, Mercer-McFadden, Mueser, McHugo, and Bond (1998) define integrated 
treatments as treatments that “simultaneously address two or more interwoven disorders” 
(p. 590). These authors state that the benefits of integrated treatment are fewer conflicts 
between treatment providers and fewer burdens on the client (i.e. transportation, 
financial). Integrated treatments are believed to be more effective then single treatments 
as they address both disorders simultaneously and thus have been suggested by a variety 
of authors (Boudewyns et al., 1991; Kofoed, Friedman, & Peck, 1993; Najavits, Weiss, & 
Shaw, 1997). 
Minkoff and Cline (2004) described a model for treating co-occurring disorders 
which included integrated treatments as a main characteristic. This model has eight 
principles that should guide integrated services: dual diagnosis is an expectation, all 
individuals with dual diagnoses are not the same, treatment relationships are highly 
valued, case management is balanced with realistic expectations, both diagnoses should 
be considered primary, both diagnoses can be treated in the same framework, 
interventions should be individualized, and outcome assessment should also be 
individualized. 
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Surveys of clients’ desires for treatment have found most expressing a desire for 
integrated treatment of their substance abuse and trauma symptomology (Back, Brady, 
Jaanimagi, & Jackson, 2006; Brown, Stout, & Gannon-Rowley, 1998; Levan, 2006; 
Najavits, Sullivan, et al., 2004). In a qualitative study by Stam (2002), women who were 
dually diagnosed reported the need for integrative treatment, but that treatment of the 
substance use should come first. This prioritization of the substance use was due to the 
fact that the participants stated they might not have been able to cope with the process of 
trauma recovery prior to abstinence.  
Steindl, Young, Creamer, and Crompton (2003) found positive outcomes with 
Australian veterans with PTSD undergoing concurrent, primarily cognitive behavioral, 
treatment for PTSD and alcohol use. These participants were divided into low risk and 
hazardous drinking groups (based on AUDIT scores). The total sample showed decreased 
PTSD and drinking symptoms, though the low risk drinking group had a greater decrease 
in symptoms than the high risk drinking group and unfortunately it is not known how 
much changes the high risk group experienced. A study of VA treatments found that 
integrated treatments had improved psychiatric symptom, employment, abstinence rate 
and aftercare outcomes than non-integrated treatments (Moggi, Ouimette, Finney, & 
Moos, 1999).  
Cocozza et al. (2005) compared the effects of nine treatment programs that 
offered integrated trauma informed treatment versus treatment as usual. Participants 
(n=2006) in both treatment and comparison sites showed statistically significant 
improvements on drug, alcohol, PTSD, and mental health outcomes at 6-month follow-up 
with participants in the treatment as usual sites showing greater improvements. Greater 
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integration of treatment showed more improvement than the treatment as usual sites or 
less integrated sites. Unfortunately, this study only provided broad treatment 
characteristics for the sites, which made it difficult to determine what specific kinds of 
treatment were the most useful.  
Seeking Safety. The Seeking Safety treatment model is the first, and currently the 
most researched, manualized treatment for dual PTSD and SUD (Najavits, 2002b). The 
model was first developed as a group treatment for women and based on four research 
literatures: SUD, PTSD, women’s treatment, and educational research (Najavits, Weiss, 
& Liese, 1996). The treatment is present-focused and focuses on helping clients learn to 
cope with current life stressors. It is designed for 25 sessions but may be longer or shorter 
as needed. Seeking Safety can be conducted with either gender and in either group or 
individual formats, and can also be integrated into other treatments (Najavits, 2002b).  
Seeking Safety has been effective with a variety of populations. The treatment has 
mainly been used with women (Najavits, Weiss, Shaw, & Muenz, 1998; Young, Hills, et 
al., 2004; Gatz et al., 2007; Mcnelis-Domingos, 2004). Its use has also been researched 
with correctional populations (Zlotnick, Najavits, Rohsenow, & Johnson, 2003; 
Hamilton, 2006), lower SES individuals (Hien, Cohen, Miele, Litt, & Capstick, 2004), 
veterans (Weller, 2005; Desai, Harpaz-Rotem, Najavits, & Rosenheck, 2008), and 
adolescents (Najavits, Gallop, & Weiss, 2006). While all of these studies demonstrated 
Seeking Safety’s effectiveness, nearly all of them were pilot studies that lacked control 
groups. 
Seeking Safety has also been explored with a Revised Exposure Therapy 
component (Najavits, Schmitz, Gotthardt, & Weiss, 2005). This combined therapy was a 
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30-session treatment lasting five months. The five male participants demonstrated 
positive results: the participants displayed perfect attendance and their PTSD and SUD 
symptoms significantly decreased. They also reported less suicidal ideation. Furthermore, 
the participants reported being very satisfied with the treatments.  
An unpublished meta-analysis found that Seeking Safety was effective in treating 
PTSD (r=.340), SUD (r=.218), and other psychological symptoms (r=.283) (Dolan, 
2008). However, Seeking Safety was not statistically significantly better than a cognitive-
behavioral coping skills relapse prevention therapy (Hien, Cohen, Miele et al., 2004).  
Exposure-Based. Some authors suggest that exposure therapies have a place in 
dual PTSD and SUD treatment (Coffey, Dansky, & Brady, 2003). One such treatment 
that incorporates exposure is Concurrent Treatment of PTSD and Cocaine Dependence 
(CTPCD) (Back, Dansky, Carroll, Foa, & Brady, 2001). CTPCD is a cognitive-
behavioral therapy for outpatients with PTSD and cocaine dependence. The main goals 
are to educate the client about the relationship between PTSD and SUD, initiate and 
maintain cocaine abstinence, and decrease PTSD symptomology. The main activities to 
accomplish these goals are psychoeducation, coping skills training, relapse prevention 
techniques, cognitive restructuring, and in-vivo and imaginal exposure therapy. The 
guidelines for the therapy note that those who have suicidal or homicidal ideation, severe 
depression, vulnerability to dissociative episodes, or who can’t stand intense affect may 
not be appropriate for the exposure components of the therapy. The treatment is mainly 
designed for inpatient and outpatient populations, though Coffey, Schumacher, Brimo, 
and Brady (2005) also describe a modification for use in community mental health 
centers. Brady, Dansky, Back, Foa, and Carroll (2001) tested the effects of CTPCD with 
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39 participants and found that while the participants had a high drop-out rate, the 
treatment was effective in reducing PTSD and SUD symptoms for those who completed 
the treatment. This last finding suggests a need for more effective engagement strategies 
to reduce high drop-out rates. 
Another treatment that incorporates exposure is the Substance-Dependence PTSD 
Therapy (SDPT) (Triffleman, 2003; Triffleman, Carroll, & Kellogg, 1999). SDPT is an 
outpatient individual therapy that is conducted twice weekly for 20 weeks. It is a 
combination of cognitive-behavioral coping skills treatment for SUD, stress inoculation 
training, and in-vivo exposure for PTSD. Exposure is conducted in a hierarchical manner 
to allow the client to set the pace and not become overwhelmed too quickly. The manual 
suggests that the treatment should be offered in conjunction with psychopharmacological 
interventions. Clients with psychotic disorders or who are on the extremes of 
homelessness are described as poor candidates for this approach “as the exigencies of 
daily living become paramount” (Triffleman, Carroll, & Kellogg, 1999, p.8). A pilot 
study of SDPT showed improvements on PTSD and SUD symptoms though SDPT was 
not statistically significantly more effective than Twelve Step Facilitation treatment 
(Triffleman, 2000).  
A third treatment that includes an exposure based treatment is Transcend, which 
is a 12-week partial hospitalization manualized treatment protocol that utilizes group 
therapy to treat dual PTSD and SUD (Donovan, Padin-Rivera, & Kowaliw, 2001). The 
main goals of the treatment involve reduction of PTSD symptoms, abstinence from 
substances, mastery of impulsive behavior, diminishment of shame, and an increase in 
self-acceptance and self-efficacy. A study of 46 combat veterans undergoing Transcend 
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treatment showed statistically significant improvements on PTSD and SUD symptoms 
that persisted all the way to a year after treatment completion (Donovan, Padin-Rivera, & 
Kowaliw, 2001).  
Other. There are a number of other integrated treatments that have been proposed 
but have yet to be empirically tested. These treatments include TARGET (Ford & Russo, 
2006), ATRIUM (Miller and Guidry, 2001), and unnamed treatment models proposed by 
Harris (1996), Brinson and Treanor (1989), Meisler (1999), Abueg and Fairbank (1991), 
Den Bleyker (2000), Evans and Sullivan (1995; Sullivan & Evans, 1996), and by Seidel, 
Gusman, and Abueg (1994).  
Other types of treatment address factors that the authors believe underlie both 
disorders. For example, Simpson, Kaysen, et al. (2007) examined the effects of 
Vipassana meditation on dual diagnosis PTSD and SUD. Vipassana meditation is a form 
of meditation that stresses mindfulness, which the authors believed to be an important 
component of recovery from the dual diagnosis. Participants who learned this meditation 
displayed less substance use at follow-up and there also was a statistically non-significant 
trend toward improvement in PTSD symptoms.  
Summary 
Many treatment manuals and guidelines have been developed for the treatment of 
dual diagnosis SUD and PTSD. Unfortunately, large numbers of rigorous empirical 
studies testing their effects have not been conducted. The studies that have been 
conducted suggest that treatment, both integrated and consecutive, is effective with this 
population, though it is not known which approach to treatment is more helpful. The 
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effect that the presence or absence of an exposure-based component has on outcomes is 
also a question that the literature has not yet adequately answered.  
There are common factors linking the various types of treatment for dual 
diagnosis SUD and PTSD. Nearly all of them have both psychoeducation and coping 
skills components. Most also stress the importance of trust issues within the therapeutic 
process and social functioning in other areas of the client’s life.  Unfortunately, because 
the lack of treatment fidelity measures is such a major methodological issue in this 
literature, it is difficult to state for certain what those common factors are. Integrated 
treatments have also generally been developed more recently, and many of these studies 
were initial pilot studies that lacked adequate control or comparison groups. 
Conclusions 
 The literature on individuals with co-occurring PTSD and SUD has focused on a 
variety of questions: (a) how does the dual diagnosis develop and maintain itself, (b) how 
does it present itself clinically, and (c) how best can this dual diagnosis be treated. The 
literature surrounding each of these areas had strengths and weaknesses. Strengths 
included the broad set of questions that have been addressed and the large number of 
different therapies that have been tested with this population. Weaknesses included 
questionable diagnostic procedures and lack of treatment reliability. Also, the pilot nature 
of many studies meant small sample sizes and lack of a control group. Other studies 
aggregated treatments and did not report enough details to determine the effectiveness of 
the specific treatments. 
There were also quite a few gaps in the literature that need to be filled. Questions 
regarding the effectiveness of integrated treatments compared with sequential treatments 
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still need to be answered. The inclusion of components such as exposure therapy also 
needs to be evaluated more thoroughly. Unfortunately, the literature does not provide 
clear answers to any of these questions at this time, though the answers could be of great 
utility in treating individuals who seek treatment for this dual diagnosis. Therefore, 
further studies should be conducted to determine if different treatment factors affect 
outcomes and should include larger sample sizes that compare various types of 
treatments. Components such as exposure should also be varied to test their effects. 
Future research should also focus on the longitudinal course of the dual disorder. 
Little is known about the etiology of the dual disorder, and more knowledge regarding 
the development of the disorders would be helpful for developing new treatments and 
possibly in treatment matching efforts. Furthermore, moderator variables, such as gender 
or substance used, should be taken into consideration, as a few studies have found these 
to be important variables (Jaycox et al., 2004; Stewart et al., 1999). The ideal study for 
examining all these factors would be a longitudinal study that regularly measured PTSD 
symptom clusters, SUD symptoms for a variety of substances, other psychological 
symptoms such as depression and coping skills, and also measured proposed vulnerability 
factors such as type of trauma.  Meta-analytic techniques that combine the results in a 
way that allow for structural equation modeling or logistic regression may also be 
extremely useful. 
Future research also needs to address the diagnostic weaknesses that have plagued 
earlier studies. Questionable diagnostic procedures could be remedied by using multiple 
sources of diagnostic information. For example, rather than relying on chart review, a 
clinical interview and/or diagnostic instrument could also be used. Psychometric data 
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should also be provided for the measurement instruments that were used. Treatment 
fidelity should also be measured and assured by training and the use of second raters. 
Detailed information on the treatments used should also be provided. 
Finally, there is a gap in the literature regarding how symptom interplay between 
the two disorders affects treatment outcomes. For example, a study by Steindl, Young, 
Creamer, and Crompton (2003) with Australian veterans undergoing concurrent treatment 
of PTSD and alcohol use found that early changes in alcohol use predicted later changes 
in PTSD symptoms. However, the reverse was not true. Improvements on one variable 
may also be found to be necessary before improvements are realized on other variables, a 
finding that would have very important treatment implications. At this point, it is not 
clear how treatment affects these symptom clusters and how these symptom clusters 
affect each other.  
Early reviews of the dual diagnosis literature called for more research (Brown & 
Wolfe, 1994) and this suggestion still holds true today. The main question yet to be 
answered in this area still revolves around the effectiveness of treatments for this dual 
diagnosis. In spite of the evidence that this dual diagnosis is difficult to treat as well as 
the many treatment models that have been proposed, there is not yet any compelling 
evidence that these new treatments are any more effective than the usual treatments. 
More outcome studies need to be conducted to determine the absolute and comparative 
effects of these proposed treatments.  
Meta-analytic techniques could also be used to compare aggregated results of 
integrated versus comparative treatments. Integrated and sequential treatments could be 
compared on PTSD, SUD, and other psychological outcomes to determine how effective 
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they are. A meta-analysis could also examine other variables such as gender, type of 
trauma, or substance of abuse to determine whether they are affecting treatment 
outcomes. While meta-analytic findings would still carry the inherent weaknesses of the 
underlying studies, it would provide clearer answers to questions regarding the 
effectiveness of different approaches to treatment for these disorders. 
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CHAPTER III 
METHODS 
The purpose of this dissertation was to meta-analytically examine the literature on 
the effectiveness of treatment for dual diagnosis PTSD and SUD. To do this, the effects 
of integrated treatments versus non-integrated treatments were compared. An exploration 
of symptom interplay between the disorders was also attempted by aggregating treatment 
follow-up data. 
“The foundation of science is the cumulation of knowledge from the results of 
many studies” (Hunter & Schmidt, 2004, p. xxvii). The results of a single study are rarely 
useful in and of themselves. The replication of results greatly increases confidence in 
conclusions, and so methods that combine and accumulate results across studies are 
extremely valuable. One method to accomplish this is to conduct a critical review of the 
literature like the one found in Chapter Two. A strength of such a review is its breadth 
and the relative ease with which it can be conducted. As Hunter and Schmidt (2004) 
demonstrated, however, conclusions from such a review can be based not on real 
differences in the data, but instead on chance variations. Meta-analysis is another form of 
knowledge accumulation that avoids many of the weaknesses of the literature review by 
combining the results in a quantitative fashion. 
The National Research Council (1992) noted that the reason to combine results is 
that each individual study represents a “noisy reading on the underlying quality of 
interest, and aggregating across them tends, under many (but not all) circumstances, to 
average out the noise to at least some extent” (p. 32). The Council further stated that in 
order to combine results across studies, the information sources need to be sufficiently 
Treatment of Dual Diagnosis 35 
 
 
similar and that the investigator is able to describe these similarities in the form of a 
model or framework. The model used in this study is shown in Figure 1 and illustrates the 
various paths of effect that treatments of this dual diagnosis are thought to take.  
Figure 1: Dual Diagnosis Treatment Path Analysis 
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There are two main areas of interest in this path diagram. The first area of interest 
involves paths E and F. These paths represent the cyclical nature of the dual disorder as 
discussed previously. These paths theoretically have positive, significant effect sizes that 
represent the possibility that increases in symptoms of one disorder will lead to increases 
in symptoms of the other disorder (Clark et al., 2001; Stewart & Conrod, 2003).  
The second area of interest concerns the effects of treatment on the disorders. 
These effects are hypothesized to be different depending on the type of treatment being 
examined. SUD treatments mainly target the SUD and are thought to be effective mainly 
on the SUD symptoms (path A; Back, Waldrop et al., 2006). The rationale for this 
treatment is that SUD symptoms first need to be lowered to a certain threshold (i.e., so 
that path E is sufficiently low) at which point the PTSD treatment is then safe and 
effective for the client to engage in (Becker, Zayfert, & Anderson, 2004). 
PTSD treatment, on the other hand, is thought to have a direct impact on PTSD 
symptoms with a moderately large effect on reducing these symptoms (path B; Powers et 
al., 2010). The effect of PTSD treatment on SUD has not been investigated as thoroughly 
(perhaps because many clinicians are worried that PTSD treatment can lead to relapse; 
Becker, Zayfert, & Anderson, 2004). There is also some evidence, however, that suggests 
that PTSD treatment is effective in treating SUD symptoms (Ouimette, Moos, and 
Finney, 2003).  
Integrated treatments are believed to have an effect on both disorders. In other 
words, the effects represented by paths C and D in Figure 1 would both be statistically 
significant. It is believed that this type of treatment would also begin to decrease the 
effects of the disorders on each other (paths E and F). 
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The purpose of this study was to begin to assign quantitative values to these paths. 
The effects of various forms of treatment (paths A – D) were the main focus of the study. 
However, the effects of the individual disorders on each other (paths E and F) during 
treatment were also secondary questions. The methodology is described in terms of the 
three stages in which it took place: literature search, coding, and the statistical analysis. 
These stages are analogous to gathering the data, transforming it into a usable form, and 
then analyzing it.  
Literature Search 
A literature search was conducted to identify published empirical outcomes 
studies for the treatment of dual diagnosis PTSD and SUD. The diagnosis of PTSD was 
first included in the 1980 version of the DSM (i.e., the DSM-III; APA, 1980) and 
consequently only studies from 1980 onwards were included. The treatment studied 
needed to be psychosocial in nature as tests of the effects of medication were beyond the 
scope of this study. Thus, studies that were purely exploring the effects of medication on 
this dual diagnosis were not included, though it was possible that participants of 
psychosocial treatment studies were also on medication to treat their symptoms. Due to 
the small number of studies that have been conducted in this area, the use of less reliable 
diagnostic procedures was not included as an exclusionary criterion in this study (e.g., 
diagnosis by chart review). The individuals needed current diagnoses for both SUD and 
PTSD and their symptoms had to be measured on at least two time points so that a 
change score correlation could be generated.  
White (1994) stated that the point of a good literature search is not to track down 
every paper on a subject (which would likely be impossible), but to avoid missing an 
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important source outside of one’s usual searches. Therefore, a broad array of sources was 
used for the current literature search including peer-reviewed journals, professional 
organizations (e.g. American Psychological Association), governmental sources, 
dissertations, and/or presentations. Five main literature search strategies were used to find 
these sources including footnote chasing, consultation, searches in subject indexes, 
browsing, and citation searches (White, 1994). Footnote chasing entailed searching 
through reference sections of major reviews in the area and through journal tables of 
content. The literature reviews consulted included those conducted by Ford, Russo, and 
Mallon (2007); Riggs and Foa (2008); Bernhardt (2009); and McClure (2009). 
Reed and Baxter (1994) discussed the importance of a comprehensive search 
strategy over a broad array of databases. PsycInfo was searched using post-traumatic 
stress disorder, alcoholism, drug abuse, and treatment as keywords. Medline was 
searched with keywords stress disorders, posttraumatic; substance related disorders and 
treatment or therapeutics. Other databases searched using combinations of PTSD and 
SUD keywords were the alcohol studies database, PILOTS database, Evidence Based 
Medicine Reviews, and the Substance Abuse and Mental Health Archive. Research 
registers are also important to search as they may include studies that were not published 
or are otherwise inaccessible (Dickersin, 1994). Thus, the National Research Register 
Archive, Clinical Trials database, and the VA Cooperative Studies Programs were 
consulted. Browsing included searching through the library stacks for similarly themed 
books. Citation searches include the use of forward citation search engines such as Social 
Sciences Citation Index for major reviews in the area. Articles used for the forward 
citation search were Stewart (1996); Najavits (1997); Ouimette (1997); Zaslav (1994); 
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and Jelinek and Williams (1984). The tables of content of journals that were consulted 
included the Journal of Dual Diagnosis, Journal of Substance Abuse Treatment, and 
Journal of Addictive Behaviors. Consultation included talking with the “invisible 
college” which is other experts in the field (Rosenthal, 1994). Authors were contacted 
who had published multiple studies in the area of co-occurring PTSD and SUD treatment. 
Coding 
Once the studies were collected, the next step was translating these data into a 
useful format, a process called coding. Appendix A contains the completed coding sheets 
for the included studies. Appendix B contains the definitions and decision rules for this 
coding. Both of these appendices were heavily influenced by Stock’s (1994) discussion 
of coding.  
The first section of the coding sheet encompassed article information and was 
mainly used to identify the article itself. This included the type of the article and date it 
was published, even though there were no reasons to believe they would be meaningful 
moderators. The next section coded was the treatment section. This section encompassed 
treatment and sample information. Multiple treatments within the same study were coded 
using separate coding sheets. Treatment strength and dosage were coded in terms of the 
number of weeks of treatment and the number of hours per week of treatment. The 
demographic variables coded included gender, race, veteran status, primary substance, 
and age. 
The final section coded for was the outcomes section which included the main 
statistics that were used in the analysis. The correlation used for this meta-analysis was 
the r statistic. The r statistic is generally viewed as the most useful correlation statistic to 
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use when variables are continuous (Rosenthal, 1994). The r2 statistic was not used 
because it does not express directionality and practical magnitude is likely to be 
misinterpreted. The d statistic was not used in the initial coding as many studies in this 
literature were pilot studies and did not include a comparison. Appendix C contains the 
formulae used to convert other statistics into the r statistic. The majority of the 
conversions made were derived from means and standard deviations. Other statistical 
information that was coded was the name and type of each measurement instrument, as 
well as their reliability coefficients. Each outcome section was repeated for multiple 
measurement times. The quality of the study was not explicitly coded as some of the 
artifact corrections helped account for quality (e.g., measurement reliability) and because 
of the general lack of reliability in the coding of study quality (Hunter & Schmidt, 2004). 
The present author was the primary coder of these data. One other individual also 
coded the statistical information for these studies as a reliability check. Disagreements 
were resolved through conferencing to arrive at consensus. These data were then entered 
into an Excel spreadsheet for data analysis.  
Orwin (1994) listed some sources of error inherent in the coding process: 
deficient reporting, ambiguities in judgment process, coder bias, and coder mistakes. 
Missing data is also a serious issue and takes three forms: missing studies, missing data to 
estimate effect sizes, and missing characteristics of studies (Pigott, 1994). Missing 
studies, such as those that were not published or accessible, were not used in this analysis 
because of lack of availability. Missing data to estimate effect sizes was a minor problem 
as occasionally only statistically significant results were reported, though other results 
were measured.  In these cases, the nonsignificant results were assumed to have an r = 
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0.0.  This assumption leads to conservative effect and variance estimates, though there 
are few other options in dealing with missing effect sizes (Pigott, 1994). Similarly, a few 
studies reported only significant results on a few subscales of an instrument. In these 
cases the unreported subscale correlations were assumed to be 0.0 and the reported and 
unreported scales were averaged to gain a single correlation for that measure. Missing 
characteristics of studies were inferred and estimated where possible from information in 
the study or from other sources (e.g., instrument reliabilities). The coding sheet and 
definitions were developed to be as simple and judgment free to minimize ambiguities, 
bias, and mistakes.  
Statistical Analysis 
This analysis used the Hunter and Schmidt (2004) model of psychometric meta-
analysis. This model of meta-analysis is a set of statistical techniques that combine data 
across studies while simultaneously correcting for various sources of error and bias 
within these results. This model of meta-analysis is a random effects model of meta-
analysis as opposed to a fixed effects model, which means that this model does not 
assume homogeneity of effect sizes between studies. This type of meta-analysis has been 
found to be more accurate than other models (Hunter & Schmidt, 2004). Other 
researchers have noted that random effects models have the advantage of being viewed as 
representative of a sample of the universe of studies on the subject, which makes them 
more generalizable (Raudenbush, 1994). 
There are a variety of sources of systematic error and bias that exist in studies that 
are correctible in a meta-analysis. Some of the more important of these sources involve 
sampling error, measurement error, and restrictions of range. The rationale behind 
Treatment of Dual Diagnosis 42 
 
 
correcting for these sources of error is that the purpose of a meta-analysis is to attain as 
accurate of a correlation coefficient to the actual population coefficient as possible 
(Hunter & Schmidt, 1994). Imperfect reliability and validity both occur when a less than 
perfect instrument is used (which is all of the time in scientific experiments). 
Dichotomization occurs when the participants are divided into two groups based on a 
point on an otherwise continuous variable. Range restriction is only accepting a certain 
subgroup of the larger population. Another source of error that must be corrected is when 
multiple measures are used to assess the same variable (Gleser & Olkin, 1994). All of 
these imperfections serve to lower the estimate of the correlation.  
Some attempts were made to correct the less than perfect reliability in the studies 
analyzed. Imperfect validity and intercorrelation between measures were not corrected 
due to a lack of psychometric data. Dichotomization and range restriction were not 
corrected for as they were not issues in this literature. The formulae used to correct for 
these sources of error can be found in Appendix D. It should be noted that some sources 
of error such as data entry cannot be corrected and remained within the effect size 
approximation (Hunter and Schmidt, 2004).  
Appendix E contains the formulae that were used to conduct the aggregation of 
corrected data. The formula for the aggregated correlation coefficient was weighted by 
two figures. The first was the sample size and the second involved the corrections that 
were used for that study. These weights assigned higher priority to studies with larger 
sample sizes and to studies that needed less correction (i.e., they were more accurate). 
Shadish and Haddock (1994) provide three assumptions that need to be met when 
deciding if and how to weigh certain studies over others: (1) theory or evidence 
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suggesting that certain studies have varying degrees of accuracy, (2) the nature of this 
bias can be estimated, and (3) appropriate weights can be given to compensate for the 
bias. Hunter and Schmidt’s (2004) weighting method met these assumptions.  
Both the observed and expected variances of these correlations were also 
calculated. The observed variance was the variance of the observed correlations, while 
the expected variance was calculated using a sampling error formula. As the goal of a 
meta-analysis is to provide an accurate estimate of the correlation and variance, the 
expected variance attributed to the sampling error was removed from the observed 
variance estimate. In some cases, the expected variance was greater than or equal to the 
observed variance. For these cases, the corrected variances were set to 0.0.  
These two variances were also compared to determine if there was some other 
source of variance that was unaccounted for. For most of the outcomes, there was a 
significant difference between the two, which indicated that there could be some 
uncorrected error or a moderator variable. At this point a moderator analysis was used to 
determine if any of the moderators that had been previously coded (e.g., treatment type, 
gender, race, dosage) served as a moderator variable. 
 Using these procedures, quantitative effect size correlations were assigned to the 
paths of Figure 1. The model used to make these assignments involved univariate data 
analysis which treated each of the paths as though they are independent of each other. 
This analysis was chosen, as opposed to other types of analyses (e.g. EM method or 
generalized least squares), due to its relative simplicity as well as the current state of the 
literature. Most studies in this analysis provided only select correlations between 
variables; as a result, the other types of analyses would be left with many omissions in 
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their correlation matrices. For these reasons, a univariate data analysis was deemed to be 
the best procedure for this model at the present time. 
Effect sizes across treatments were compared to determine if integrated versus 
consecutive treatments are more effective. For comparison of treatments, the statistic 
Cohen’s d was used. Effect sizes across time were plotted to determine if reductions in 
certain symptoms predicted changes in other sets of symptoms.  
Clinical significance is another important consideration when attempting to 
address questions regarding treatment effectiveness. Clinical significance has been 
defined as the “extent to which therapy moves someone outside the range of the 
dysfunctional population or within the range of the functional population” (Hageman & 
Arrindell, 1999, pp. 1169-1170). The use of clinical significance allows the classification 
of clients undergoing treatment into those who are unchanged or deteriorated, those who 
are improved but not recovered, and those who have recovered. Within the context of a 
meta-analysis, Hageman and Arrindell (1999) suggest estimating the proportion of clients 
experiencing positive change versus those that did not experience positive change as a 
means of calculating clinical significance. To this end, a binomial effect size display was 
employed.  
The final step was a publication bias analysis (Begg, 1994). Publication bias 
exists when only certain studies get published. These published studies are theorized to 
be the ones that have higher effect sizes, which then leads to an upward bias in meta-
analytic results. One method to avoid this biased sampling frame is to include as many 
studies as possible. For this reason a comprehensive literature search strategy was used. 
To test for the presence of publication bias, a funnel graph was used. A funnel graph plots 
Treatment of Dual Diagnosis 45 
 
 
effect size against sample size and if no publication bias is present then this graph should 
look like a funnel in which smaller sample size studies have a greater spread of 
correlations and higher sample size are more narrowly concentrated around the midpoint. 
Hunter and Schmidt’s (2004) file drawer analysis based on effect size was used to 
determine how many studies averaging null results would be needed to bring the 
observed correlations down to a predetermined critical value. 
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CHAPTER IV 
RESULTS 
The initial literature search yielded 124 studies that discussed treatment for dual 
diagnosis for SUD and PTSD. After closer inspection of these studies, seventeen of these 
were found to meet the inclusion criteria set for this study. One report was excluded as it 
was a case study. Four were excluded as they were primarily medication studies. Forty-
six studies were excluded because they did not include statistics necessary for this meta-
analysis (e.g., no pre-post measurements). Another forty-four were excluded because the 
sample population did not meet the inclusion criteria of this meta-analysis (e.g., SUD and 
trauma, but not necessarily PTSD). Seven studies were excluded because the data 
reported was used in other studies that were included in this analysis. Five studies were 
not included as they could not be obtained by the primary author. These studies were 
requested through interlibrary loan and by contacting the primary authors when contact 
information was available, but were still not attained. Characteristics of those studies that 
were included in this analysis can be found in Table 1. These studies yielded 101 
individual correlations that were then used in the meta-analysis. 
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Table 1 
Study Characteristics 
Study Treatment Outcomes Measured O    r N  n 
Back, Jackson, 
Sonne, Brady, 
2005 
CB coping 
skills therapy 
for SUD 
Post PTSD total 
Post SUD ETOH 
.64 
.50 
86 
86 
Brady, Dansky, 
Back, Foa, 
Carroll, 2001 
Integrated 
CTCPD 
Post PTSD total 
Post PTSD re-experiencing 
Post PTSD arousal 
Post PTSD avoidance 
Post SUD Drug 
Post SUD ETOH 
Post General psych 
6 month PTSD total 
6 month PTSD re-
experiencing 
6 month PTSD arousal 
6 month PTSD avoidance 
6 month SUD Drug 
6 month SUD ETOH 
6 month General psych 
.49 
.44 
.37 
.45 
.62 
.38 
.38 
.61 
.28 
 
.61 
.56 
.71 
.55 
.92 
15 
15 
15 
15 
15 
15 
15 
7 
7 
 
7 
7 
7 
7 
7 
Brown, 2000 Inpatient SUD 6 month PTSD total 
6 month Drug & ETOH 
.43 
.62 
29 
29 
Brown, Read, 
Kahler, 2003 
Inpatient SUD 6 month PTSD total 
6 month SUD Drug & ETOH 
6 month General psych 
.46 
.56 
.56 
52 
52 
52 
Coffey, 
Schumacher, 
Brady, Cotton, 
2007 
In and 
outpatient SUD 
Post PTSD total 
Post PTSD re-experiencing 
Post PTSD arousal 
Post PTSD avoidance 
.19 
-.01 
.13 
.20 
45 
45 
45 
45 
Cook, Walser, 
Kane, Ruzek, 
Woody, 2006 
 
 
 
 
 
 
 
 
 
 
 
 
Integrated 
Seeking Safety 
Post PTSD total .52 18 
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Study Treatment Outcomes Measured     r N   n 
Donovan, Padin-
Rivera, Kowaliw, 
2001 
Integrated 
Transcend 
Post PTSD total 
Post PTSD re-experiencing 
Post PTSD arousal 
Post PTSD avoidance 
6 month PTSD total 
6 month PTSD re-
experiencing 
6 month PTSD arousal 
6 month PTSD avoidance 
6 month SUD Drug 
6 month SUD ETOH 
1 year PTSD total 
1 year PTSD re-experiencing 
1 year PTSD arousal 
1 year PTSD avoidance 
1 year SUD Drug 
1 year SUD ETOH 
.32 
.21 
.25 
.30 
.29 
.26 
 
.21 
.27 
.35 
.40 
.30 
.23 
.17 
.33 
.33 
.40 
46 
46 
46 
46 
46 
46 
 
46 
46 
46 
46 
46 
46 
46 
46 
46 
46 
McGovern, 
Lambert-Harris, 
Acquilano, Xie, 
Alterman, Weiss, 
2009 
Integrated CBT 
for PTSD 
Post PTSD total 
Post PTSD re-experiencing 
Post PTSD arousal 
Post PTSD avoidance 
Post SUD Drug 
Post SUD ETOH 
3 month PTSD total 
3 month PTSD re-
experiencing 
3 month PTSD arousal 
3 month PTSD avoidance 
3 month SUD Drug 
3 month SUD ETOH 
.80 
.74 
.58 
.76 
.23 
.41 
.86 
.77 
 
.66 
.84 
.29 
.27 
11 
11 
11 
11 
11 
11 
10 
10 
 
10 
10 
10 
10 
Najavits, Harned, 
Gallop, Butler, 
Barber, Thase, 
Crits-Cristoph, 
2007 
Various SUD 3 month SUD Drug 
3 month SUD ETOH 
6 month SUD Drug 
6 month SUD ETOH 
3 month General psych 
6 month General psych  
.63 
.19 
.65 
.10 
.09 
.16 
34 
34 
34 
34 
34 
34 
Najavits, Gallop, 
Weiss, 2006 
Integrated 
Seeking Safety 
Post SUD Drug & ETOH 
Post General psych 
3 month SUD Drug & ETOH 
3 month General psych 
.55 
.12 
.17 
-.18 
18 
18 
18 
18 
Najavits, Gallop, 
Weiss, 2006 
(same as previous 
article) 
 
Non-integrated 
treatment as 
usual 
Post SUD Drug & ETOH 
Post General psych 
3 month SUD Drug & ETOH 
3 month General psych 
.18 
.01 
.33 
.10 
15 
15 
15 
15 
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Study Treatment Outcomes Measured      r      n 
Najavits, Schmitz, 
Gotthardt, Weiss, 
2005 
Integrated 
Seeking Safety 
with exposure 
treatment 
Post PTSD total 
POST SUD Drug 
Post General psych 
.85 
.81 
.09 
5 
5 
5 
 
Najavits, Weiss, 
Shaw, Muenz, 
1998 
Integrated 
Seeking Safety 
Post PTSD Total 
Post SUD Drug 
Post SUD ETOH 
Post General psych 
3 month PTSD total 
3 month SUD Drug 
3 month SUD ETOH 
3 month General psych 
.00 
.26 
.00 
.00 
.28 
.20 
.00 
.00 
11 
11 
11 
11 
11 
11 
11 
11 
Norman, Wilkins, 
Tapert, Lang, 
Najavits, n.d. 
Integrated 
Seeking Safety 
Post PTSD total 
Post SUD ETOH 
Post General psych 
3 month PTSD total 
3 month SUD ETOH 
3 month General psych 
6 month PTSD total 
6 month SUD ETOH 
6 month General psych 
.31 
.22 
.41 
.75 
.49 
.74 
.55 
.55 
.19 
9 
9 
9 
4 
4 
4 
4 
4 
4 
Ouimette, Ahrens, 
Moos, Finney, 
1997 
Various SUD 1 year SUD Drug 
1 year SUD ETOH 
1 year General psych 
.29 
.31 
.06 
140 
140 
140 
Ouimette, Ahrens, 
Moos, Finney, 
1998 
Inpatient SUD Post General psych .46 140 
Ouimette, Finney, 
Moos, 1999 
Various SUD 2 year SUD Drug 
2 year SUD ETOH 
2 year General psych 
.30 
.32 
.09 
135 
135 
135 
Zlotnick, 
Najavits, 
Rohsenow, 
Johnson, 2003 
Integrated 
Seeking Safety 
Post PTSD total 
Post SUD Drug 
Post SUD ETOH 
3 month PTSD total 
3 month SUD Drug 
3 month SUD ETOH 
.69 
.00 
.00 
.52 
.78 
.81 
17 
17 
17 
15 
15 
15 
  
These correlations were divided into seven different symptom categories: PTSD 
total, PTSD arousal, PTSD avoidance, PTSD re-experiencing, SUD alcohol, SUD other 
drugs, and other psychological symptoms. These categories were also divided into 
measurement time to analyze treatment effects over time. These divisions were 
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immediately post-treatment and three months, six months, twelve months, and twenty-
four months post-treatment.  
Treatment effects 
 The first research question dealt with the absolute effectiveness of treatment on 
dual diagnosis PTSD and SUD. For this question, only immediate post-treatment means 
were used. The mean treatment effects for PTSD total symptoms was r = .46 (SD = .14, 
95% CI = .38 - .54, n = 292, N = 11), for PTSD arousal symptoms was r = .25 (SD = 0.0, 
n = 117, N = 4), for PTSD avoidance symptoms was r = .32 (SD = 0.0, n = 91, N = 4), for 
PTSD re-experiencing symptoms was r = .20 (SD = .14, 95% CI = .07 - .34, n = 117, N = 
4), for SUD alcohol symptoms was r = .40 (SD = .09, 95% CI = .34 - .46, n = 211, N = 
9), for SUD drug symptoms was r = .46 (SD = .13, 95% CI = .37 - .54, n = 155, N = 9), 
and other psychological symptoms was r = .36 (SD = .39, 95% CI = .08 - .65, n = 213, N 
= 7). Some corrected standard deviations were found to be 0.0, which precluded the 
computation of confidence intervals. As can be seen from the confidence intervals, all of 
these effects were statistically significant, which suggests that treatment for this dual 
diagnosis is effective at reducing symptoms for PTSD, SUD, and other general 
psychological symptoms. Stem and leaf plots for these analyses are displayed in Figure 2. 
Binomial effect size displays that show clinical significance can be found in Figure 3. 
These displays show the percentage of participants who had shown positive change after 
treatment.  
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Figure 2: Stem and leaf displays of corrected treatment effect correlations 
Stem Leaf  Stem Leaf  Stem Leaf 
 .9 0  .9   .9  
.8 3  .8   .8  
.7 1  .7   .7 8 
.6 6  .6   .6  
.5 1 5  .5 8  .5  
.4 4  .4   .4 7 
.3 3 3  .3 7  .3 1 
.2   .2 5  .2 0 
.1 9  .1 3  .1  
.0 0  .0   .0  
-.01   -.01   -.01  
Total PTSD  Arousal 
PTSD 
 Avoidance 
PTSD 
        
Stem Leaf  Stem Leaf  Stem Leaf 
.9   .9   .9  
.8   .8   .8 3 
.7 6  .7 0  .7 0 
.6   .6 0  .6 0 4 5 
.5   .5 6  .5  
.4 6  .4 1 5  .4  
.3   .3   .3  
.2 2  .2 0 5  .2 0 5 7 
.1   .1   .1  
.0   .0 0 0  .0 0 
-.01 0  -.01   -.01  
Re-experiencing 
PTSD 
 SUD Alcohol  SUD Drug 
        
Stem Leaf       
.9        
.8        
.7        
.6        
.5        
.4 3 7       
.3 9       
.2        
.1 3       
.0 0 1 9       
-.01        
Other       
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Figure 3: Percentage of participants with improvement after treatment 
 More/Equal 
Symptoms 
Less 
Symptoms 
  More/Equal 
Symptoms 
Less 
Symptoms 
Pre-
Treatment 
73% 27%  Pre-
Treatment 
62.5% 37.5% 
Post- 
Treatment 
27% 73%  Post- 
Treatment 
37.5% 62.5% 
Total PTSD Symptoms  PTSD Arousal Symptoms 
       
 More/Equal 
Symptoms 
Less 
Symptoms 
  More/Equal 
Symptoms 
Less 
Symptoms 
Pre-
Treatment 
66% 34%  Pre-
Treatment 
60% 40% 
Post- 
Treatment 
34% 66%  Post- 
Treatment 
40% 60% 
PTSD Avoidance Symptoms  PTSD Re-experiencing Symptoms 
       
 More/Equal 
Symptoms 
Less 
Symptoms 
  More/Equal 
Symptoms 
Less 
Symptoms 
Pre-
Treatment 
70% 30%  Pre-
Treatment 
72.5% 27.5% 
Post- 
Treatment 
30% 70%  Post- 
Treatment 
27.5% 72.5% 
SUD Alcohol Symptoms  SUD Drug Symptoms 
       
 More/Equal 
Symptoms 
Less 
Symptoms 
    
Pre-
Treatment 
68% 32%     
Post- 
Treatment 
32% 58%     
Other Symptoms     
 
Sequential vs. Integrated Treatments 
 The second research question dealt with the question of the difference between 
sequential and integrated treatments. Post-treatment means were exclusively used for this 
analysis (not follow-up means). Most of the treatment effect sizes were derived from 
integrated treatments (N=34) while the remaining were from SUD-focused treatments 
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(N=14). Integrated and SUD focused treatment statistics can be found in Table 2. Positive 
d statistics represent better results for SUD-focused treatments. SUD-focused treatments 
displayed significantly better results for SUD alcohol symptoms and non-significantly 
better results for PTSD total symptoms, SUD drug symptoms, and other symptoms. The 
only symptoms clusters that integrated treatments showed better results were PTSD 
arousal, PTSD avoidance symptoms, and PTSD re-experiencing symptoms, though the 
inability to compute confidence intervals due to variances = 0.0 precluded the ability to 
assess statistical significance. The symptom clusters showed better results than the PTSD 
total symptoms because only the least effective SUD treatment studies contributed effect 
sizes to the individual symptom cluster analysis. The path model with attached effect 
sizes can be found in Figure 4. Treatment effects for the SUD path were attained by 
computing the mean effect size of SUD alcohol and SUD drug symptoms. The PTSD 
treatment model was dropped due to the lack of studies on PTSD-only treatment with this 
dual diagnosis population that met the inclusion criteria.   
Table 2 
 
Integrated vs. SUD-focused Treatments 
Symptom Treatment r SD 95% CI N d 
PTSD total SUD-focused 
Integrated 
.47 
.45 
.16 
.09 
.29 - .66 
.39 - .51 
3 
8 
.20 
PTSD 
arousal 
SUD-focused 
Integrated 
.13 
.33 
0.0 
0.0 
- 
- 
1 
3 
- 
PTSD 
avoidance 
SUD-focused 
Integrated 
.20 
.40 
0.0 
0.0 
- 
-  
1 
3 
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Symptom Treatment r SD 95% CI N d 
PTSD re-
experiencing 
SUD-focused 
Integrated 
-.01 
.34 
0.0 
.06 
- 
.27 - .40 
1 
3 
-8.25 
 
SUD 
alcohol 
SUD-focused 
Integrated 
.49 
.27 
.04 
0.0 
.44 – .53 
-  
3 
6 
11.67 
SUD drug SUD-focused 
Integrated 
.54 
.37 
.10 
.07 
.42 – .66 
.31 - .43 
3 
6 
2.42 
Other SUD-focused 
Integrated 
.42 
.21 
.19 
.37 
.16 – .68 
-.11 - .53 
2 
5 
.73 
Note. Some confidence intervals and d statistics could not be calculated due to SD = 0 
Figure 4: Dual Diagnosis Treatment Path Analysis 
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Moderator Variables 
 The third research question focused on whether there were any other moderating 
influences on treatment outcomes. To address this question, Hunter and Schmidt’s (2004) 
“75% rule” was used. This criterion compares the observed variance to the variance that 
would be expected given the average correlation and number of studies to determine how 
much of the variance was accounted for through artifact and sampling error. If the 
expected variance accounts for at least 75% of the observed variance, then it is concluded 
that there are no other moderating variables as  the remaining variance is assumed to be 
due to unaccounted for artifact error. According to Hunter and Schmidt (2004), this 
method has better or equal power in determining if there was a moderator than other 
methods, a finding that applied especially when the number of studies in the meta-
analysis was small, which was this case with the present analysis. 
 Most of the symptom clusters post-treatment failed the 75% rule suggesting that 
other moderating influences were involved: total PTSD symptoms (56.4% of the variance 
accounted for), SUD drug symptoms (68.5% of the variance accounted for), other 
symptoms (14.6% of the variance accounted for), and PTSD re-experiencing (62.9% of 
the variance accounted for). PTSD avoidance symptoms (100% of the variance accounted 
for), PTSD arousal symptoms (100% of the variance accounted for), SUD alcohol 
symptoms (79.4% of the variance accounted for) did not appear to be influenced by any 
moderators.  
 Thus, a moderator analysis was conducted using the following moderators: article 
date, exposure component, number of study participants, treatment dosage (measured by 
total treatment hours where available), age of participants, gender of participants, race of 
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participants, and type of substance use disorder (dependence or abuse).  None of the 
coded variables were found to be clear moderators for PTSD total symptoms. The 
number of subjects in a study was found to moderate the effects on SUD drug symptoms 
with low n studies (less than 20 participants) having a mean r = .34 (SD = 0) and high n 
studies having a mean r = .63 (SD=0) and on PTSD re-experiencing symptoms with low 
n studies having a mean r = .57 (SD = 0) and high n studies having a mean r = .10 
(SD=0). Other symptoms appeared to be moderated by the racial composition of the 
participants as studies with higher proportions of racial minorities (one third or more of 
the sample) having a mean of r = .06 (SD=0) and lower proportions having a mean of r = 
.45 (SD=0). Caution should be taken when interpreting these results, especially given the 
contradictory findings regarding how the number of participants moderates the results.   
Treatment over time 
 The fourth research question dealt with the effectiveness of treatment over time 
with individuals with dual PTSD and SUD. Treatment over time effects can be found in 
Figure 5. Some of these follow-up data were based on studies that also presented 
immediate post-treatment effects (e.g. Donovan, Padin-Rivera, Kowaliw, 2001) while 
others presented only follow-up data (e.g. Brown, Read, Kahler, 2003). A few studies 
presented serial data using the same participants over time. For example, Ouimette, 
Ahrens, Moos, and Finney (1997) presented one-year follow-up data and Ouimette, 
Finney, and Moos (1999) presented two-year data for the same participants. 
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Figure 5: Treatment over time mean correlation effects 
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Total PTSD symptoms showed a relatively large effect initially with r = .46 (SD = 
.14, 95% CI = .38 - .54, n = 292, N = 11) and a slow linear decrease after a year (r =.30, 
SD = 0, n = 46, N = 1). All three PTSD symptom clusters showed similar trajectories. 
After 3 months, each symptom cluster showed a large increase in effect size. This 
increase was due to the effect size coming from a single study and is thus not reflective of 
a true 3-month post-treatment decrease in symptoms. After this increase in effect size, 
each of the symptom clusters displayed a relatively consistent effect to what was seen 
initially post-treatment. 
 The SUD symptoms showed medium effect sizes initially: for alcohol symptoms, 
r = .40 (SD = .09, 95% CI = .34 - .46, n = 211, N = 9) and for drug symptoms, r = .46 
(SD = .13, 95% CI = .37 - .54, n = 155, N = 9). These effects were relatively stable even 
after two years with alcohol symptoms increasing slightly (r = .31, SD = 0, n = 135, N = 
1) and drug symptoms increasing the same amount (r = .30, SD = 0, n = 135, N = 1). 
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Other psychological symptoms were much more inconsistent.  Post-treatment effect size 
was r = .36 (SD = .39, 95% CI = .08 - .65, n = 213, N = 7). This effect was nearly erased 
after three months (r = .05, SD = 0.0,  n = 82, N = 5) though returned after six months (r 
= .27, SD = .08, 95% CI = .19 - .34, n = 97, N = 4). One year and two year measurements 
were then negligible: at one-year, r = .06 (SD = 0, n = 140, N = 1) and at two years, r = 
.09 (SD = 0, n = 135, N = 1). 
 There was no evidence of interplay between the symptoms. Both PTSD and SUD 
symptoms showed initial gains with slow decreases over time. There were no indications 
from the data or graphs that either of these symptoms was affecting the other. 
Publication bias 
The final step of this meta-analysis entailed determining whether there was a 
publication bias in the studies included in the analysis. A funnel graph with all of the 
study correlations is found in Figure 6. A funnel plot theoretically should be symmetrical 
with effect sizes clustered around the true effect size. Studies with low numbers of 
participants should have more sampling error and thus be more spread out near the 
bottom of the plot, producing the shape of a funnel. As can be seen from Figure 6, there 
is a slight asymmetry to the right. Asymmetry is generally indicative of publication bias 
as it suggests that studies with smaller effect sizes are not being published. It may also be 
due to a third factor that relates the sample size to the size of effect. For example, smaller 
sample size studies may be more prone to error or have more intense treatment, leading to 
exaggerated effect sizes (Sutton, 2009). The results of this analysis are suggestive, but not 
entirely diagnostic of publication bias, and these results consequently may represent an 
over-estimate of the true population effect size. 
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As these results suggested the presence of the “file drawer problem,” Hunter and 
Schmidt’s file drawer analysis based on effect size was used to determine how many 
studies with null results would need to be found to bring the observed correlations down 
to a predetermined critical value. For this analysis, the critical value chosen was r=.10 as 
this value would be considered a weak result and many of the observed correlations were 
in the medium to strong range. The number of null result studies needed to decrease these 
results to a weak level for PTSD total symptoms was 40, PTSD arousal was 6, PTSD 
avoidance was 9, PTSD re-experiencing was 4, SUD alcohol was 27, SUD drug was 33, 
and other psychological symptoms was 19. Therefore, while there may be a publication 
bias leading to an over-estimate of effect sizes, it is likely that this bias would not greatly 
weaken these results as the number of studies with null results would need to be about 
three times the number of studies that were actually found measuring PTSD total, SUD 
alcohol, SUD drug, and other psychological symptoms, while there would need to be 
about two times the number of studies measuring the individual PTSD symptom clusters. 
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Figure 6. Publication bias funnel graph 
 
0
20
40
60
80
100
120
140
160
-0.5 0 0.5 1
n
effect size
Treatment of Dual Diagnosis 64 
 
 
CHAPTER V 
DISCUSSION 
Major Findings 
The meta-analysis conducted in this study set out to answer four main questions. 
The first of these questions focused on the effectiveness of treatment for this dual 
diagnosis. Post-treatments effects were all statistically non-zero. Wampold (2000) 
reported that the best point estimate for the effectiveness of psychotherapy compared to a 
control group was d = .80, which converts to r = .37. The effective sizes in the present 
study (r = .46 for PTSD symptoms and SUD drug symptoms, r = .40 for SUD alcohol 
symptoms, and r = .36 for other psychological symptoms) are either larger or similar to 
Wampold’s point estimate for the effectiveness of psychotherapy in general, though it 
should be noted that the present findings compare pre- to post-treatment changes rather 
than treatment to control groups. While some literature has described this population as 
difficult to treat, (e.g., Najavits, 2002a) these findings suggest that treatment is as 
effective with this population as it is with others. 
The second question compared various kinds of treatment on PTSD and SUD 
symptoms. SUD-focused treatments were more effective than integrated treatments for 
treating SUD symptoms with d = 11.67 for alcohol use symptoms and d = 2.42 for drug 
use symptoms. SUD-focused treatments were also more effective for treating other 
psychological symptoms with d = .73 and total PTSD symptoms:d =.20. The only 
symptoms that were decreased more in integrated treatments than in SUD-focused 
treatments were the individual PTSD symptom clusters which appeared to result from 
Treatment of Dual Diagnosis 65 
 
 
having only the least effective SUD treatment studies contribute effect sizes to that 
analysis.  
These results were not expected as they contradicted the literature that suggested 
that integrated treatments should display greater effects than singular treatments 
(Boudewyns et al., 1991; Kofoed, Friedman, & Peck, 1993; Najavits, Weiss, & Shaw, 
1997). While it might not be surprising that SUD-focused treatments had greater effects 
on SUD symptoms, it is surprising that there was little difference in PTSD effects. It is 
possible that this is due to SUD symptoms being the main driver of symptomology for 
this dual diagnosis and focusing mainly on the SUD decreases symptoms across the dual 
diagnosis. It is also possible that while SUD-focused treatments are ostensibly focused on 
SUD symptoms, PTSD symptoms are also being addressed by the therapist either 
explicitly or implicitly. Further research would need to be done regarding symptom 
interplay and treatment factors to determine if either of these possibilities apply. These 
findings do suggest caution, however, in embracing newer integrated treatments over 
more established SUD-focused therapies. Integrated treatments are not contraindicated as 
they showed positive effects in the present study, but more research would need to be 
done to show that they are more effective than singularly focused treatments. 
The third research question focused on possible moderating influences on the 
treatment effect sizes.  This analysis found that the number of participants moderated two 
of the symptom clusters, though the direction of moderation was inconsistent with larger 
numbers of participants leading to better results for SUD drug symptoms, but weaker 
results for PTSD re-experiencing. Hunter and Schmidt (2004) caution against the use of 
exploratory moderator analyses, especially with small numbers of studies, and the 
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inconsistency of these results suggests that they may be spurious. The moderator analysis 
also found that race of participants may be a moderating influence for other 
psychological symptoms. While there is reason to believe that treatments can have 
differing effects on different populations (Chambless et al., 1996), this result should be 
interpreted cautiously due to the aforementioned low number of studies and inconsistency 
of results.  
The fourth research question explored treatment over time effects. The major 
symptom clusters of this dual diagnosis (i.e., total PTSD symptoms, drug SUD 
symptoms, and alcohol SUD symptoms) all displayed relatively stable effect sizes over 
time. These effects only decreased slightly up to two years post-treatment. The other 
symptom clusters showed much more variable patterns. The PTSD symptom clusters 
showed a sudden leap in effectiveness at three months, but this was due to the single 
study that contributed an effect size at that time point. The relative variability of other 
psychological symptoms over time was puzzling as more effect sizes were involved in 
that analysis, though the broad range of symptoms included in this category may have 
contributed to the variability. More research would need to be done measuring these 
symptoms with this population to achieve more stable results. The relative stability with 
only minor decreases over time was a positive result. Further research could be done on 
the effectiveness of “booster” sessions after treatment to determine if even these minor 
decreases could be avoided. 
One of the questions that the treatment over time analysis was intended to shed 
light on was a question of symptom interplay. It was hoped that there might be some 
evidence of one symptom showing a consistent improvement prior to the other; but that 
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was not found to be the case. This does not necessarily preclude the possibility that one 
of the symptoms tends to drive the other, as is hypothesized by the self-medication 
hypothesis and similar theories. It is possible that this symptom interplay is still taking 
place, but the measurement times used in this study (e.g., at post-treatment, 3-months, 
etc.) were not precise enough to find it.  
Generalizability of Results 
 This meta-analysis utilized a random-effects model of analysis, which means that 
inferences to similar treatments can be made. Thus, these results can be thought to apply 
to individuals with dual diagnosis PTSD and SUD who are undergoing either SUD-
focused or integrated treatments for these issues. Only a third (three out of nine) of the 
integrated treatments were non-Seeking Safety treatments. Thus, the low numbers of non-
Seeking Safety treatments limits the ability to generalize to those other treatments. Also, 
because there were no studies in the analysis that utilized PTSD-focused therapy, these 
results cannot be applied to individuals undergoing that type of therapy for this dual 
diagnosis. Only a single study examined the effects of treatment with an adolescent 
sample, which decreases the ability to apply these results to a non-adult population.  
Limitations and Guidelines for Future Research 
The small number of studies included in the meta-analysis was the most serious of 
the limitations of the current study. A meta-analysis depends on having a strong base of 
literature to provide reliable aggregated results from which reliable conclusions can be 
drawn. In the present analysis, 17 studies resulting in 101 effect sizes were found, which 
would usually be an adequate number of effect sizes, but when these studies were further 
subdivided by symptom and measurement time, they yielded inadequate numbers for 
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some of the analyses. Specifically, the moderator analyses found contradictory results, 
which may have been due to the lack of stability and low number of studies. This 
weakness will decrease as more research continues to be done on the topic. Future 
research publications should also include all the study results, whether significant or not. 
It was apparent in some articles gathered for this analysis that data had been gathered, but 
it was not reported due to statistical non-significance or for other unknown reasons. The 
missing data analysis also suggested that the “file drawer” problem in which non-
significant results are not being reported appears to be an issue in this literature. 
Another limitation involved the lack of information on treatment adherence on the 
part of treatment providers. This meta-analysis made a variety of comparisons between 
different types of treatment and lack of treatment adherence information sheds some 
doubt on the results. For example, if some of the SUD-focused treatments did include 
aspects of PTSD treatment, they should have been coded as integrated in the present 
study, which would have likely led to different results and conclusions. 
Similarly, the lack of diagnostic certainty was an issue in some studies. For 
example, some of the studies used past diagnoses of SUD and/or PTSD as diagnostic 
criteria. Further information on the reliability of these past diagnoses would have been 
helpful in assuring that this analysis only included individuals who met the inclusion 
criteria. 
As mentioned earlier, another weakness of this study was that it was ill-equipped 
to explore the interplay between SUD and PTSD symptoms. To explore this issue, future 
studies would need to use much more frequent outcome measurement, ideally conducted 
on at least a weekly basis. Unfortunately, at present there are no studies to this author’s 
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knowledge that have used this type of frequent outcome measurement, and so this issue 
cannot be explored using meta-analysis, though this knowledge could be a great aid in 
designing treatments for this dual diagnosis. 
Another weakness to this study was that portions of the analysis were conducted 
solely by the primary author. The effect sizes and the statistical components of the 
analysis were double-checked by a second individual and any differences were resolved 
through consensus. However, much of the work in study selection was done by a single 
individual and the resulting lack of “quality checks” in this phase of data collection may 
have possibly led to some form of systematic bias in study inclusion or exclusion. It 
would have been preferable to use a team of researchers to conduct all phases of the data 
collection and analysis in the present study.  
Conclusion 
 The symptoms and other issues experienced by those with the dual diagnosis of 
PTSD and SUD have profound effects on the lives of these individuals. The present study 
aggregated the results from several studies that examined how best to help these 
individuals. While this analysis found encouraging results showing that treatment is 
helpful in reducing symptoms in this population, the lack of stability in those results was 
also disheartening. In addition, no evidence was found for any increased efficacy of the 
newer integrated treatments for this dual diagnosis over SUD-only focused treatments. 
These issues need more research examination, and more efforts are needed to develop 
new treatments that will be more effective with this population.  Future research into 
these issues will be very helpful to the many individuals who suffer from SUD and PTSD 
dual diagnosis for finding the help that they need.  
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Appendix A: Completed Coding Worksheets 
 
Article Information 
Article ID: 1 Title: Changes in PTSD symptomatology during acute and protracted 
alcohol and cocaine abstinence 
Authors: Coffey, S. F., Schumacher, J. A., Brady, K. T., & Cotton, B. D. 
Type of article:1 Date: 2007 
Treatment (Independent Variable)  
Type of Treatment: 2 Treatment Subtype: 77% op; 23% ip + op Exposure: 0 
Treatment Dosage: 4w Weekly Dosage: n/a      
Demographics of Sample 
Age: 33.6   Female%: 52   Caucasian%: n/a   African-American%: n/a  
Asian American%: n/a   Latino%: n/a   American Indian%: n/a   Other%: n/a  
%Vets: n/a  Primary Substance(s): 30% cocaine; 23% ETOH; 47% both 
SUD Type: D   Trauma Type: multiple Dropout%: 20 
Outcomes (Dependent Variable)  
 Total PTSD symptoms 
Observed Correlation: .19 Sample Size: 45    Measurement Time: post 
Measurement Instrument: MPSS  Measurement Type: 1 
Instrument Reliability: n/a 
Re-experiencing PTSD symptoms 
Observed Correlation: -.01 Sample Size: 45    Measurement Time: post 
Measurement Instrument: MPSS  Measurement Type: 1 
Instrument Reliability: n/a 
Treatment of Dual Diagnosis 108 
 
 
Hyperarousal PTSD symptoms 
Observed Correlation: .13 Sample Size: 45    Measurement Time: post 
Measurement Instrument: MPSS  Measurement Type: 1 
Instrument Reliability: n/a 
Avoidance PTSD symptoms 
Observed Correlation: .20 Sample Size: 45    Measurement Time: post 
Measurement Instrument: MPSS  Measurement Type: 1 
Instrument Reliability: n/a  
SUD alcohol symptoms 
Observed Correlation: n/a Sample Size:     Measurement Time:  
Measurement Instrument:   Measurement Type:  
Instrument Reliability: 
SUD drug symptoms 
Observed Correlation: n/a  Sample Size:     Measurement Time:  
Measurement Instrument:   Measurement Type:  
Instrument Reliability: 
Other symptoms 
Observed Correlation: n/a Sample Size:     Measurement Time:  
Measurement Instrument:    Measurement Type:  
Instrument Reliability:   What measured:    
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Article Information 
Article ID: 2  Title: During treatment changes in substance abuse patients with 
posttraumatic stress disorder  
Authors: Ouimette, P. C., Ahrens, C., Moos, R. H., Finney, J. W.   
Type of article: 1  Date:  1998 
Treatment (Independent Variable)  
Type of Treatment: 2  Treatment Subtype: ip Exposure: 0  
Treatment Dosage: 4w Weekly Dosage: n/a      
Demographics of Sample 
Age: 44.93    Female%: 0     Caucasian%: 55.5   African-American%: 44.5 
Asian American%: 0  Latino%: 0  American Indian%: 0  Other%: 0 
%Vets: 100  Primary Substance(s): 53.6 ETOH; 18.6 drugs; 27.9 both 
SUD Type: A    Trauma Type: n/a (majority assumed combat Dropout%: 5.7 
Outcomes (Dependent Variable)  
Total PTSD symptoms 
Observed Correlation: n/a Sample Size:     Measurement Time:  
Measurement Instrument:   Measurement Type:  
Instrument Reliability:  
Re-experiencing PTSD symptoms 
Observed Correlation: n/a Sample Size:     Measurement Time:  
Measurement Instrument:   Measurement Type:  
Instrument Reliability:  
Hyperarousal PTSD symptoms 
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Observed Correlation: n/a Sample Size:     Measurement Time:  
Measurement Instrument:   Measurement Type:  
Instrument Reliability:  
Avoidance PTSD symptoms 
Observed Correlation: n/a Sample Size:     Measurement Time:  
Measurement Instrument:   Measurement Type:  
Instrument Reliability:  
SUD alcohol symptoms 
Observed Correlation: n/a Sample Size:     Measurement Time:  
Measurement Instrument:   Measurement Type:  
Instrument Reliability: 
SUD drug symptoms 
Observed Correlation: n/a Sample Size:     Measurement Time:  
Measurement Instrument:   Measurement Type:  
Instrument Reliability: 
Other symptoms 
Observed Correlation: .46 Sample Size: 140     Measurement Time: post 
Measurement Instrument: BSI  Measurement Type: 1 
Instrument Reliability: .94 What measured: general psych symptoms 
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Article Information 
Article ID: 6  Title: Six-month treatment outcomes of cocaine-dependent patients 
with and without PTSD in a multisite national trial 
Authors: Najavits, L. M., Harned M. S., Gallop, R. J., Butler, S. F., Barber, J. P., Thase, 
M. E., Crits-Christoph, P.  Type of article: 1  Date: 2007  
Treatment (Independent Variable)  
Type of Treatment: 2  Treatment Subtype: various  Exposure: 0 
Treatment Dosage: 6m  Weekly Dosage: various      
Demographics of Sample 
Age: 32.71 Female%: 47.1   Caucasian%: 55.9   African-American%: 41.2 
Asian American%: n/a  Latino%: n/a  American Indian%: n/a  Other%: 2.9  
%Vets: n/a Primary Substance(s): 100 cocaine; 44.1 ETOH; 2.9 cannibis; 2.9 
sedatives 
SUD Type: D    Trauma Type: various Dropout%: 76.5 
Outcomes (Dependent Variable)  
Total PTSD symptoms 
Observed Correlation: n/a Sample Size:     Measurement Time:  
Measurement Instrument:   Measurement Type:  
Instrument Reliability:  
Re-experiencing PTSD symptoms 
Observed Correlation: n/a Sample Size:     Measurement Time:  
Measurement Instrument:   Measurement Type:  
Instrument Reliability:  
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Hyperarousal PTSD symptoms 
Observed Correlation: n/a Sample Size:     Measurement Time:  
Measurement Instrument:   Measurement Type:  
Instrument Reliability:  
Avoidance PTSD symptoms 
Observed Correlation: n/a Sample Size:     Measurement Time:  
Measurement Instrument:   Measurement Type:  
Instrument Reliability:  
SUD alcohol symptoms 
Observed Correlation: .19 Sample Size: 34     Measurement Time: 3m 
Measurement Instrument: ASI ETOH Measurement Type: 1 
Instrument Reliability: n/a 
SUD alcohol symptoms 
Observed Correlation: .10  Sample Size: 34     Measurement Time: 6m 
Measurement Instrument: ASI ETOH Measurement Type: 1 
Instrument Reliability: n/a 
SUD drug symptoms 
Observed Correlation: .63 Sample Size: 34    Measurement Time: 3m 
Measurement Instrument: ASI Drug  Measurement Type: 1 
Instrument Reliability: n/a 
SUD drug symptoms 
Observed Correlation: .65 Sample Size: 34     Measurement Time: 6m 
Measurement Instrument: ASI drug  Measurement Type: 1 
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Instrument Reliability: n/a 
Other symptoms 
Observed Correlation: .09 Sample Size: 34     Measurement Time: 3m 
Measurement Instrument: BSI  Measurement Type: 1 
Instrument Reliability: n/a What measured: general psych symptoms  
Other symptoms 
Observed Correlation: .16 Sample Size: 34     Measurement Time: 6m 
Measurement Instrument: BSI  Measurement Type: 1 
Instrument Reliability: n/a  What measured: general psych symptoms  
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Article Information 
Article ID: 7  Title: Posttraumatic stress disorder in substance abuse patients: 
relationship to 1-year posttreatment outcomes 
Authors: Ouimette, P. C., Ahrens, C., Moos, R. H., Finney, J. W. 
Type of article: 1  Date:  1997 
Treatment (Independent Variable)  
Type of Treatment: 2  Treatment Subtype: various  Exposure: 0 
Treatment Dosage: 3-4w  Weekly Dosage: n/a      
Demographics of Sample 
Age: 44.88    Female%: 0    Caucasian%: 57.9   African-American%: 42.1 
Asian American%:  n/a Latino%: n/a  American Indian%: n/a  Other%: n/a 
%Vets: 100  Primary Substance(s): n/a 
SUD Type: A    Trauma Type: n/a  Dropout%: 12 
Outcomes (Dependent Variable)  
Total PTSD symptoms 
Observed Correlation: n/a Sample Size:     Measurement Time:  
Measurement Instrument:   Measurement Type:  
Instrument Reliability:  
Re-experiencing PTSD symptoms 
Observed Correlation: n/a Sample Size:     Measurement Time:  
Measurement Instrument:   Measurement Type:  
Instrument Reliability:  
Hyperarousal PTSD symptoms 
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Observed Correlation: n/a Sample Size:     Measurement Time:  
Measurement Instrument:   Measurement Type:  
Instrument Reliability:  
Avoidance PTSD symptoms 
Observed Correlation: n/a Sample Size:     Measurement Time:  
Measurement Instrument:   Measurement Type:  
Instrument Reliability:  
SUD alcohol symptoms 
Observed Correlation: .31 Sample Size: 140    Measurement Time: 1y 
Measurement Instrument: Alcohol consumption via Health & Daily Living Form  
Measurement Type: 1 Instrument Reliability:n/a 
SUD drug symptoms 
Observed Correlation: .29 Sample Size: 140    Measurement Time: 1y 
Measurement Instrument: Problems from Substance Use Scale 
 Measurement Type: 1 Instrument Reliability:n/a 
Other symptoms 
Observed Correlation: .06 Sample Size: 140    Measurement Time: 1y 
Measurement Instrument: BSI  Measurement Type: 1 
Instrument Reliability: .94 What measured:  general psych symptoms  
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Article Information 
Article ID: 8 Title: Two-year posttreatment functioning and coping of substance abuse 
patients with posttraumatic stress disorder 
Authors: Ouimette, P. C., Finney, J. W., Moos, R. H. Type of article: 1  Date: 1999  
Treatment (Independent Variable)  
Type of Treatment: 2   Treatment Subtype: various   Exposure: 0 
Treatment Dosage: 3-4w  Weekly Dosage: n/a       
Demographics of Sample 
Age: 42.83    Female%: 0    Caucasian%: 57   African-American%: 43 
Asian American%: 0  Latino%: 0   American Indian%: 0  Other%: 0 
%Vets: 100  Primary Substance(s): 52.1 ETOH; 20 drug; 28.9 both 
SUD Type: A    Trauma Type: n/a  Dropout%: n/a 
Outcomes (Dependent Variable)  
Total PTSD symptoms 
Observed Correlation: n/a Sample Size:     Measurement Time:  
Measurement Instrument:   Measurement Type:  
Instrument Reliability:  
Re-experiencing PTSD symptoms 
Observed Correlation: n/a Sample Size:     Measurement Time:  
Measurement Instrument:   Measurement Type:  
Instrument Reliability:  
Hyperarousal PTSD symptoms 
Observed Correlation: n/a Sample Size:     Measurement Time:  
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Measurement Instrument:   Measurement Type:  
Instrument Reliability:  
Avoidance PTSD symptoms 
Observed Correlation: n/a Sample Size:     Measurement Time:  
Measurement Instrument:   Measurement Type:  
Instrument Reliability:  
SUD alcohol symptoms 
Observed Correlation: .32 Sample Size: 135    Measurement Time: 2y 
Measurement Instrument: Alcohol consumption via Health & Daily Living Form  
Measurement Type: 1 Instrument Reliability: n/a 
SUD drug symptoms 
Observed Correlation: .30 Sample Size: 135    Measurement Time: 2y 
Measurement Instrument: Problems from Substance Use Scale 
Measurement Type: 1 Instrument Reliability: n/a 
Other symptoms 
Observed Correlation: .09 Sample Size: 135     Measurement Time: 2y 
Measurement Instrument: BSI Measurement Type: 1 
Instrument Reliability: .94 What measured:   general psych symptoms 
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Article Information 
Article ID: 11   Title: A cognitive behavioral therapy for co-occuring substance use 
and posttraumatic stress disorders 
Authors: McGovern, M. P., Lambert-Harris, Chantel, Acquilano, S., Xie, H., Alterman, 
A. I. Weiss, R. D.   Type of article: 1  Date:  2009 
Treatment (Independent Variable)  
Type of Treatment: 1  Treatment Subtype: CBT for PTSD Exposure: 0 
Treatment Dosage: 4-6w  Weekly Dosage: 9-12h      
Demographics of Sample 
Age: 34    Female%: 91    Caucasian%: 100   African-American%: 0 
Asian American%: 0  Latino%: 0  American Indian%: 0  Other%: 0 
%Vets: n/a  Primary Substance(s): n/a 
SUD Type: n/a    Trauma Type: n/a   Dropout%: 9 
Outcomes (Dependent Variable)  
Total PTSD symptoms 
Observed Correlation: .80  Sample Size: 11     Measurement Time: post 
Measurement Instrument: CAPS  Measurement Type: 1 
Instrument Reliability: n/a 
Total PTSD symptoms 
Observed Correlation: .86  Sample Size: 10     Measurement Time: 3m 
Measurement Instrument: CAPS  Measurement Type: 1 
Instrument Reliability: n/a 
Re-experiencing PTSD symptoms 
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Observed Correlation: .74 Sample Size: 11     Measurement Time: post 
Measurement Instrument: CAPS  Measurement Type: 1  
Instrument Reliability: n/a 
Re-experiencing PTSD symptoms 
Observed Correlation: .77 Sample Size: 10     Measurement Time: 3m 
Measurement Instrument: CAPS  Measurement Type: 1  
Instrument Reliability: n/a 
Hyperarousal PTSD symptoms 
Observed Correlation: .58 Sample Size: 11     Measurement Time: post 
Measurement Instrument: CAPS  Measurement Type: 1 
Instrument Reliability: n/a 
Hyperarousal PTSD symptoms 
Observed Correlation: .66 Sample Size: 10     Measurement Time: 3m 
Measurement Instrument: CAPS  Measurement Type: 1 
Instrument Reliability: n/a 
Avoidance PTSD symptoms 
Observed Correlation: .76 Sample Size: 11    Measurement Time: post 
Measurement Instrument: CAPS  Measurement Type: 1 
Instrument Reliability: n/a 
Avoidance PTSD symptoms 
Observed Correlation: .84 Sample Size: 10    Measurement Time: 3m 
Measurement Instrument: CAPS  Measurement Type: 1 
Instrument Reliability: n/a 
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SUD alcohol symptoms 
Observed Correlation: .41 Sample Size: 11     Measurement Time: post 
Measurement Instrument: TLFB + ASI ETOH  Measurement Type: 1 
Instrument Reliability: n/a 
SUD alcohol symptoms 
Observed Correlation: .42 Sample Size: 10     Measurement Time: 3m 
Measurement Instrument: TLFB + ASI ETOH  Measurement Type: 1 
Instrument Reliability: n/a 
SUD drug symptoms 
Observed Correlation: .23 Sample Size: 11    Measurement Time: post 
Measurement Instrument: TLFB +ASI drug  Measurement Type: 1 
Instrument Reliability: n/a 
SUD drug symptoms 
Observed Correlation: .25 Sample Size: 10    Measurement Time: 3m 
Measurement Instrument: TLFB +ASI drug  Measurement Type: 1 
Instrument Reliability: n/a 
Other symptoms 
Observed Correlation: n/a Sample Size:     Measurement Time:  
Measurement Instrument:   Measurement Type:  
Instrument Reliability:  What measured:    
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Article Information 
Article ID: 12  Title: Alcohol dependence and posttraumatic stress disorder: 
differences in clinical presentation and response to cognitive-behavioral therapy by order 
of onset 
Authors: Back, S. E., Jackson, J. L, Sonne, S., Brady, K. T. 
Type of article: 1  Date:  2005 
Treatment (Independent Variable)  
Type of Treatment: 2  Treatment Subtype: CB Coping Skills Therapy 
Exposure: 0   Treatment Dosage: 12w  Weekly Dosage: n/a      
Demographics of Sample 
Age: 36.62    Female%: 48   Caucasian%: 85.1   African-American%: 11.7 
Asian American%: 0  Latino%: 1.1  American Indian%: 2.1  Other%: 0 
%Vets: n/a Primary Substance(s): ETOH 
SUD Type: D    Trauma Type: n/a  Dropout%: 34.9 
Outcomes (Dependent Variable)  
Total PTSD symptoms 
Observed Correlation: .64 Sample Size: 86    Measurement Time: post 
Measurement Instrument: IES, MISS, CAPS Measurement Type: 1 
Instrument Reliability: n/a 
Re-experiencing PTSD symptoms 
Observed Correlation: n/a Sample Size:     Measurement Time:  
Measurement Instrument:   Measurement Type:  
Instrument Reliability:  
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Hyperarousal PTSD symptoms 
Observed Correlation: n/a Sample Size:     Measurement Time:  
Measurement Instrument:   Measurement Type:  
Instrument Reliability:  
Avoidance PTSD symptoms 
Observed Correlation: n/a Sample Size:     Measurement Time:  
Measurement Instrument:   Measurement Type:  
Instrument Reliability:  
SUD alcohol symptoms 
Observed Correlation: .50 Sample Size: 86    Measurement Time: post 
Measurement Instrument: TLFB  Measurement Type: 1 
Instrument Reliability: n/a 
SUD drug symptoms 
Observed Correlation: n/a Sample Size:     Measurement Time:  
Measurement Instrument:   Measurement Type:  
Instrument Reliability: 
Other symptoms 
Observed Correlation: n/a Sample Size:     Measurement Time:  
Measurement Instrument:   Measurement Type:  
Instrument Reliability:  What measured:    
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Article Information 
Article ID: 15  Title: Dissemination and feasibility of a cognitive-behavioral 
treatment for substance use disorders and posttraumatic stress disorder in the veterans 
administration 
Authors: Cook, J. M., Walser, R.D., Kane, V., Ruzek, J. I., Woody, G. 
Type of article: 1 Date:  2008 
Treatment (Independent Variable)  
Type of Treatment: 1  Treatment Subtype: Seeking Safety Exposure: 0 
Treatment Dosage: n/a Weekly Dosage: n/a      
Demographics of Sample 
Age: 50    Female%: 28   Caucasian%: n/a   African-American%: n/a 
Asian American%: n/a   Latino%: n/a  American Indian%: n/a  Other%: n/a 
%Vets:100  Primary Substance(s): 78 ETOH, 61cocaine, 33 heroin 
SUD Type: A    Trauma Type: n/a   Dropout%: 28 
Outcomes (Dependent Variable)  
Total PTSD symptoms 
Observed Correlation: .52  Sample Size: 18    Measurement Time: post 
Measurement Instrument: PCL-Military Measurement Type: 1 
Instrument Reliability:  
Re-experiencing PTSD symptoms 
Observed Correlation: n/a  Sample Size:     Measurement Time:  
Measurement Instrument:   Measurement Type:  
Instrument Reliability:  
Treatment of Dual Diagnosis 124 
 
 
Hyperarousal PTSD symptoms 
Observed Correlation: n/a Sample Size:     Measurement Time:  
Measurement Instrument:   Measurement Type:  
Instrument Reliability:  
Avoidance PTSD symptoms 
Observed Correlation: n/a Sample Size:     Measurement Time:  
Measurement Instrument:   Measurement Type:  
Instrument Reliability:  
SUD alcohol symptoms 
Observed Correlation: n/a Sample Size:     Measurement Time:  
Measurement Instrument:   Measurement Type:  
Instrument Reliability: 
SUD drug symptoms 
Observed Correlation: n/a Sample Size:     Measurement Time:  
Measurement Instrument:   Measurement Type:  
Instrument Reliability: 
Other symptoms 
Observed Correlation: n/a Sample Size:     Measurement Time:  
Measurement Instrument:   Measurement Type:  
Instrument Reliability:  What measured:    
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Article Information 
Article ID: 16  Title: “Transcend”: initial outcomes from a posttraumatic stress 
disorder/substance abuse treatment program 
Authors: Donovan, B., Padin-Rivera, E., Kowaliw, S. Type of article: 1 Date:  2001 
Treatment (Independent Variable)  
Type of Treatment: 1  Treatment Subtype: Transcend Exposure: 1 
Treatment Dosage: 12w   Weekly Dosage: 10h      
Demographics of Sample 
Age: 49   Female%: 0    Caucasian%: 61    African-American%:  37 
Asian American%: 0  Latino%: 2  American Indian%: 0  Other%: 0 
%Vets: 100  Primary Substance(s): 30 ETOH 70 poly 
SUD Type: A    Trauma Type: n/a   Dropout%: 10 
Outcomes (Dependent Variable)  
Total PTSD symptoms 
Observed Correlation: .32 Sample Size: 46    Measurement Time: post 
Measurement Instrument: CAPS  Measurement Type: 1 
Instrument Reliability: n/a 
Total PTSD symptoms 
Observed Correlation: .29 Sample Size: 46    Measurement Time: 6m 
Measurement Instrument: CAPS  Measurement Type: 1 
Instrument Reliability: n/a 
Total PTSD symptoms 
Observed Correlation: .30 Sample Size: 46    Measurement Time: 1y 
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Measurement Instrument: CAPS  Measurement Type: 1 
Instrument Reliability: n/a 
Re-experiencing PTSD symptoms 
Observed Correlation: .21  Sample Size: 46     Measurement Time: post 
Measurement Instrument: CAPS   Measurement Type: 1 
Instrument Reliability: n/a 
Re-experiencing PTSD symptoms 
Observed Correlation: .26  Sample Size: 46     Measurement Time: 6m 
Measurement Instrument: CAPS   Measurement Type: 1 
Instrument Reliability: n/a 
 Re-experiencing PTSD symptoms 
Observed Correlation: .23  Sample Size: 46     Measurement Time: 1y 
Measurement Instrument: CAPS   Measurement Type: 1 
Instrument Reliability: n/a 
Hyperarousal PTSD symptoms 
Observed Correlation: .25  Sample Size: 46     Measurement Time: post 
Measurement Instrument: CAPS  Measurement Type: 1 
Instrument Reliability: n/a 
Hyperarousal PTSD symptoms 
Observed Correlation: .21  Sample Size: 46     Measurement Time: 6m 
Measurement Instrument: CAPS  Measurement Type: 1 
Instrument Reliability: n/a 
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Hyperarousal PTSD symptoms 
Observed Correlation: .17  Sample Size: 46     Measurement Time: 1y 
Measurement Instrument: CAPS  Measurement Type: 1 
Instrument Reliability: n/a 
Avoidance PTSD symptoms 
Observed Correlation: .30 Sample Size: 46    Measurement Time: post  
Measurement Instrument: CAPS   Measurement Type: 1 
Instrument Reliability: n/a 
Avoidance PTSD symptoms 
Observed Correlation: .27 Sample Size: 46    Measurement Time: 6m  
Measurement Instrument: CAPS   Measurement Type: 1 
Instrument Reliability: n/a 
Avoidance PTSD symptoms 
Observed Correlation: .33 Sample Size: 46    Measurement Time: 1y  
Measurement Instrument: CAPS   Measurement Type: 1 
Instrument Reliability: n/a 
SUD alcohol symptoms 
Observed Correlation: .40 Sample Size: 46    Measurement Time: 6m 
Measurement Instrument: ASI ETOH  Measurement Type: 1 
Instrument Reliability: n/a 
SUD alcohol symptoms 
Observed Correlation: .40 Sample Size: 46    Measurement Time: 1y 
Measurement Instrument: ASI ETOH  Measurement Type: 1 
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Instrument Reliability: n/a 
SUD drug symptoms 
Observed Correlation: .35 Sample Size: 46    Measurement Time: 6m 
Measurement Instrument: ASI drug  Measurement Type: 1 
Instrument Reliability: n/a 
SUD drug symptoms 
Observed Correlation: .33 Sample Size: 46    Measurement Time: 1y 
Measurement Instrument: ASI drug  Measurement Type: 1 
Instrument Reliability: n/a 
Other symptoms 
Observed Correlation: n/a Sample Size:     Measurement Time:  
Measurement Instrument:   Measurement Type:  
Instrument Reliability:  What measured:    
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Article Information 
Article ID: 27  Title: “Seeking Safety”: outcome of a new cognitive-behavioral 
psychotherapy for women with posttraumatic stress disorder and substance dependence 
Authors: Najavits, L. M., Weiss, R. D., Shaw, S. R., Muenz, L. R. 
Type of article: 1  Date:  1998 
Treatment (Independent Variable)  
Type of Treatment: 1  Treatment Subtype: Seeking Safety Exposure: 0 
Treatment Dosage: 12w   Weekly Dosage: 3h/w      
Demographics of Sample 
Age: 35.9    Female%: 100   Caucasian%: 88   African-American%: 12 
Asian American%: 0  Latino%: 0  American Indian%: 0  Other%: 0 
%Vets: n/a  Primary Substance(s): 41 ETOH, 41 Drug, 18 Both  
SUD Type: D     Trauma Type: various Dropout%: 37 
Outcomes (Dependent Variable)  
Total PTSD symptoms 
Observed Correlation: .28  Sample Size: 11    Measurement Time: 3m 
Measurement Instrument: TSC-40  Measurement Type: 1 
Instrument Reliability: n/a 
Re-experiencing PTSD symptoms 
Observed Correlation: n/a Sample Size:     Measurement Time:  
Measurement Instrument:   Measurement Type:  
Instrument Reliability:  
Hyperarousal PTSD symptoms 
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Observed Correlation: n/a Sample Size:     Measurement Time:  
Measurement Instrument:   Measurement Type:  
Instrument Reliability:  
Avoidance PTSD symptoms 
Observed Correlation: n/a Sample Size:     Measurement Time:  
Measurement Instrument:   Measurement Type:  
Instrument Reliability:  
SUD alcohol symptoms 
Observed Correlation: n/a Sample Size:     Measurement Time:  
Measurement Instrument:   Measurement Type:  
Instrument Reliability: 
SUD drug symptoms 
Observed Correlation: .26 Sample Size: 11    Measurement Time: post 
Measurement Instrument: ASI drug  Measurement Type: 1 
Instrument Reliability: n/a 
SUD drug symptoms 
Observed Correlation: .20 Sample Size: 11    Measurement Time: 3m 
Measurement Instrument: ASI drug  Measurement Type: 1 
Instrument Reliability: n/a 
Other symptoms 
Observed Correlation: n/r Sample Size:     Measurement Time:  
Measurement Instrument:   Measurement Type:  
Instrument Reliability:  What measured:    
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Article Information 
Article ID: 28a   Title: Seeking Safety therapy for adolescent girls with 
PTSD and substance use disorder: a randomized controlled trial 
Authors: Najavits, L. M., Gallop, R. J., Weiss, R. D. Type of article: 1  Date:  2006 
Treatment (Independent Variable)  
Type of Treatment: 1   Treatment Subtype: Seeking Safety   Exposure: 0 
Treatment Dosage: 3m  Weekly Dosage:    2h   
Demographics of Sample 
Age: 16.06    Female%: 100   Caucasian%: 78.8   African-American%: 3 
Asian American%: 12.1  Latino%: 3  American Indian%: 0  Other%: 3 
%Vets: 0  Primary Substance(s): ETOH + drug 
SUD Type: A    Trauma Type: various  Dropout%: n/a 
Outcomes (Dependent Variable)  
Total PTSD symptoms 
Observed Correlation: n/a Sample Size:     Measurement Time:  
Measurement Instrument:   Measurement Type:  
Instrument Reliability:  
Re-experiencing PTSD symptoms 
Observed Correlation: n/a Sample Size:     Measurement Time:  
Measurement Instrument:   Measurement Type:  
Instrument Reliability:  
Hyperarousal PTSD symptoms 
Observed Correlation: n/a Sample Size:     Measurement Time:  
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Measurement Instrument:   Measurement Type:  
Instrument Reliability:  
Avoidance PTSD symptoms 
Observed Correlation: n/a Sample Size:     Measurement Time:  
Measurement Instrument:   Measurement Type:  
Instrument Reliability:  
SUD alcohol symptoms 
Observed Correlation: .55 Sample Size: 18    Measurement Time: post 
Measurement Instrument: APS SUD  Measurement Type: 1 
Instrument Reliability: n/a 
SUD alcohol symptoms 
Observed Correlation: .17  Sample Size: 18     Measurement Time: 3m 
Measurement Instrument: APS SUD  Measurement Type: 1 
Instrument Reliability: n/a 
SUD drug symptoms 
Observed Correlation: .55 Sample Size: 18    Measurement Time: post 
Measurement Instrument: APS SUD  Measurement Type: 1 
Instrument Reliability: n/a 
SUD drug symptoms 
Observed Correlation: .17  Sample Size: 18     Measurement Time: 3m 
Measurement Instrument: APS SUD  Measurement Type: 1 
Instrument Reliability: n/a 
Other symptoms 
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Observed Correlation: .12  Sample Size: 18     Measurement Time: post 
Measurement Instrument: APS depression  Measurement Type: 1 
Instrument Reliability: n/a What measured:   depression 
Other symptoms 
Observed Correlation: .-.18  Sample Size: 18     Measurement Time: 3m 
Measurement Instrument: APS depression  Measurement Type: 1 
Instrument Reliability: n/a What measured:   depression 
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Article Information 
Article ID: 28b Title: Seeking Safety therapy for adolescent girls with PTSD and 
substance use disorder: a randomized controlled trial 
Authors: Najavits, L. M., Gallop, R. J., Weiss, R. D. Type of article: 1  Date:  2006 
Treatment (Independent Variable)  
Type of Treatment: 2   Treatment Subtype: n/a   Exposure: 0 
Treatment Dosage: n/a  Weekly Dosage:    n/a   
Demographics of Sample 
Age: 16.06    Female%: 100   Caucasian%: 78.8   African-American%: 3 
Asian American%: 12.1  Latino%: 3  American Indian%: 0  Other%: 3 
%Vets: 0  Primary Substance(s): ETOH + drug 
SUD Type: A    Trauma Type: various  Dropout%: n/aOutcomes 
(Dependent Variable)  
Total PTSD symptoms 
Observed Correlation: n/a Sample Size:     Measurement Time:  
Measurement Instrument:   Measurement Type:  
Instrument Reliability:  
Re-experiencing PTSD symptoms 
Observed Correlation: n/a Sample Size:     Measurement Time:  
Measurement Instrument:   Measurement Type:  
Instrument Reliability:  
Hyperarousal PTSD symptoms 
Observed Correlation: n/a Sample Size:     Measurement Time:  
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Measurement Instrument:   Measurement Type:  
Instrument Reliability:  
Avoidance PTSD symptoms 
Observed Correlation: n/a Sample Size:     Measurement Time:  
Measurement Instrument:   Measurement Type:  
Instrument Reliability:  
SUD alcohol symptoms 
Observed Correlation: .18 Sample Size: 15    Measurement Time: post 
Measurement Instrument: APS SUD  Measurement Type: 1 
Instrument Reliability: n/a 
SUD alcohol symptoms 
Observed Correlation: .33 Sample Size: 15    Measurement Time: 3m 
Measurement Instrument: APS SUD  Measurement Type: 1 
Instrument Reliability: n/a 
SUD drug symptoms 
Observed Correlation: .18 Sample Size: 15    Measurement Time: post 
Measurement Instrument: APS SUD  Measurement Type: 1 
Instrument Reliability: n/a 
SUD drug symptoms 
Observed Correlation: .33 Sample Size: 15    Measurement Time: 3m 
Measurement Instrument: APS SUD  Measurement Type: 1 
Instrument Reliability: n/a 
 
Treatment of Dual Diagnosis 136 
 
 
Other symptoms 
Observed Correlation: .01  Sample Size: 15    Measurement Time: post 
Measurement Instrument: APS depression  Measurement Type: 1 
Instrument Reliability:  n/a What measured:   depression 
Other symptoms 
Observed Correlation: .10  Sample Size: 15    Measurement Time: 3m 
Measurement Instrument: APS depression  Measurement Type: 1 
Instrument Reliability:  n/a What measured:   depression 
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Article Information 
Article ID:29   Title: Seeking safety plus exposure therapy: an outcome study on 
dual diagnosis men  Authors: Najavits, L. M., Schmitz, M., Gotthardt, S., Weiss, R. D. 
Type of article: 1 Date:  2005 
Treatment (Independent Variable)  
Type of Treatment: 1  Treatment Subtype: Seeking Safety + Exposure 
Exposure: 1 Treatment Dosage: 5m   Weekly Dosage:  30 sessions total     
Demographics of Sample 
Age: 37.6    Female%: 0     Caucasian%: 100   African-American%: 0 
Asian American%: 0  Latino%: 0  American Indian%: 0  Other%: 0 
%Vets: 0  Primary Substance(s): various 
SUD Type: D    Trauma Type: various  Dropout%: 0 
Outcomes (Dependent Variable)  
Total PTSD symptoms 
Observed Correlation: .85 Sample Size: 5    Measurement Time: post 
Measurement Instrument: TSC-40  Measurement Type: 1 
Instrument Reliability: n/a 
Re-experiencing PTSD symptoms 
Observed Correlation: n/a Sample Size:     Measurement Time:  
Measurement Instrument:   Measurement Type:  
Instrument Reliability:  
Hyperarousal PTSD symptoms 
Observed Correlation: n/a Sample Size:     Measurement Time:  
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Measurement Instrument:   Measurement Type:  
Instrument Reliability:  
Avoidance PTSD symptoms 
Observed Correlation: n/a Sample Size:     Measurement Time:  
Measurement Instrument:   Measurement Type:  
Instrument Reliability:  
SUD alcohol symptoms 
Observed Correlation: n/a Sample Size:     Measurement Time:  
Measurement Instrument:   Measurement Type:  
Instrument Reliability: 
SUD drug symptoms 
Observed Correlation: .81 Sample Size: 5     Measurement Time: post 
Measurement Instrument: ASI drug  Measurement Type: 1 
Instrument Reliability: n/a 
Other symptoms 
Observed Correlation: .09 Sample Size: 5     Measurement Time: post 
Measurement Instrument: BSI  Measurement Type: 1 
Instrument Reliability: n/a What measured:  general psych symptoms  
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Article Information 
Article ID: 30  Title: Outcome in female patients with both substance use and 
post-traumatic stress disorders  Authors: Brown, P. J. Type of article: 1 Date:  2000 
Treatment (Independent Variable)  
Type of Treatment: 2  Treatment Subtype: ip Exposure: 0 
Treatment Dosage: n/a  Weekly Dosage: n/a       
Demographics of Sample 
Age: 35.24    Female%: 100   Caucasian%: 86   African-American%: n/a 
Asian American%: n/a  Latino%: n/a  American Indian%: n/a  Other%: n/a 
%Vets: n/a  Primary Substance(s): 35 ETOH, 35 drug, 31 both 
SUD Type: na    Trauma Type: various   Dropout%: 0 
Outcomes (Dependent Variable)  
Total PTSD symptoms 
Observed Correlation: .43 Sample Size: 29     Measurement Time: 6m 
Measurement Instrument: CAPS  Measurement Type: 1 
Instrument Reliability: n/a 
Re-experiencing PTSD symptoms 
Observed Correlation: n/a Sample Size:     Measurement Time:  
Measurement Instrument:   Measurement Type:  
Instrument Reliability:  
Hyperarousal PTSD symptoms 
Observed Correlation: n/a Sample Size:     Measurement Time:  
Measurement Instrument:   Measurement Type:  
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Instrument Reliability:  
Avoidance PTSD symptoms 
Observed Correlation: n/a Sample Size:     Measurement Time:  
Measurement Instrument:   Measurement Type:  
Instrument Reliability:  
SUD alcohol symptoms 
Observed Correlation: .62 Sample Size: 29    Measurement Time: 6m 
Measurement Instrument: TLFB  Measurement Type: 1 
Instrument Reliability: n/a 
SUD drug symptoms 
Observed Correlation: .62 Sample Size: 29     Measurement Time: 6m 
Measurement Instrument: TLFB  Measurement Type: 1 
Instrument Reliability: n/a 
Other symptoms 
Observed Correlation: n/a Sample Size:     Measurement Time:  
Measurement Instrument:   Measurement Type:  
Instrument Reliability:  What measured:    
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Article Information 
Article ID: 31  Title: Exposure therapy in the treatment of PTSD among cocaine-
dependent individuals: preliminary findings 
Authors: Brady, K. T., Dansky, B. S., Back, S. E., Foa, E. B., Carroll, K. M.   
Type of article: 1  Date:  2001 
Treatment (Independent Variable)  
Type of Treatment: 1  Treatment Subtype: Exposure and relapse prevention 
Exposure: 1  Treatment Dosage: 16w  Weekly Dosage: 1-3h      
Demographics of Sample 
Age: 33.5    Female%: 86.7   Caucasian%: 53.3    African-American%: 46.7 
Asian American%: 0  Latino%: 0  American Indian%: 0  Other%: 0 
%Vets: n/a Primary Substance(s): cocaine 
SUD Type: D    Trauma Type: various   Dropout%: 62 
Outcomes (Dependent Variable)  
Total PTSD symptoms 
Observed Correlation: .49 Sample Size:  15   Measurement Time: post 
Measurement Instrument: MISS, IES, CAPS Measurement Type: 1 
Instrument Reliability: n/a 
Total PTSD symptoms 
Observed Correlation: .67 Sample Size:  7   Measurement Time: 6m 
Measurement Instrument: MISS, IES, CAPS Measurement Type: 1 
Instrument Reliability: n/a 
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Re-experiencing PTSD symptoms 
Observed Correlation: .44 Sample Size: 15    Measurement Time: post 
Measurement Instrument: IES, CAPS  Measurement Type: 1 
Instrument Reliability: n/a 
Re-experiencing PTSD symptoms 
Observed Correlation: .28 Sample Size: 7    Measurement Time: 6mt 
Measurement Instrument: IES, CAPS  Measurement Type: 1 
Instrument Reliability: n/a 
Hyperarousal PTSD symptoms 
Observed Correlation: .37 Sample Size: 15    Measurement Time: post 
Measurement Instrument: CAPS  Measurement Type: 1 
Instrument Reliability: n/a 
Hyperarousal PTSD symptoms 
Observed Correlation: .61 Sample Size: 7    Measurement Time: 6m 
Measurement Instrument: CAPS  Measurement Type: 1 
Instrument Reliability: n/a 
Avoidance PTSD symptoms 
Observed Correlation: .45 Sample Size: 15    Measurement Time: post 
Measurement Instrument: IES, CAPS Measurement Type: 1 
Instrument Reliability: n/a 
Avoidance PTSD symptoms 
Observed Correlation: .56 Sample Size: 7    Measurement Time: 6m 
Measurement Instrument: IES, CAPS Measurement Type: 1 
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Instrument Reliability: n/a 
SUD alcohol symptoms 
Observed Correlation: .38 Sample Size: 15     Measurement Time: post 
Measurement Instrument: ASI ETOH  Measurement Type: 1 
Instrument Reliability: n/a 
SUD alcohol symptoms 
Observed Correlation: .55 Sample Size: 7     Measurement Time: 6m 
Measurement Instrument: ASI ETOH  Measurement Type: 1 
Instrument Reliability: n/a 
SUD drug symptoms 
Observed Correlation: .62  Sample Size: 15     Measurement Time: post 
Measurement Instrument: ASI drug  Measurement Type: 1 
Instrument Reliability: n/a 
SUD drug symptoms 
Observed Correlation: .71  Sample Size: 7     Measurement Time: 6m 
Measurement Instrument: ASI drug  Measurement Type: 1 
Instrument Reliability: n/a 
Other symptoms 
Observed Correlation: .38 Sample Size: 15    Measurement Time: post 
Measurement Instrument: BDI  Measurement Type: 1 
Instrument Reliability:  n/a  What measured:   depression 
Other symptoms 
Observed Correlation: .92 Sample Size: 7    Measurement Time: 6m 
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Measurement Instrument: BDI  Measurement Type: 1 
Instrument Reliability:  n/a  What measured:   depression 
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Article Information 
Article ID: 33  Title: A cognitive-behavioral treatment for incarcerated women 
with substance abuse disorder and posttraumatic stress disorder: findings from a pilot 
study  Authors: Zlotnick, C, Najavits, L. M., Rohsenow, D. J., Johnson, D. M.  
Type of article: 1 Date:  2003 
Treatment (Independent Variable)  
Type of Treatment: 1  Treatment Subtype: Seeking Safety Exposure: 0 
Treatment Dosage: 12w  Weekly Dosage:  3h     
Demographics of Sample 
Age: 31.9   Female%: 100   Caucasian%: 66.7   African-American%: 11.1 
Asian American%: 0  Latino%: 5.6  American Indian%: 0  Other%: 16.7 
%Vets: n/a  Primary Substance(s): 50 cocaine, 22.2 ETOH and drugs 
SUD Type: D    Trauma Type: various  Dropout%: n/a 
Outcomes (Dependent Variable)  
Total PTSD symptoms 
Observed Correlation: .69 Sample Size: 18    Measurement Time: post 
Measurement Instrument: CAPS  Measurement Type: 1 
Instrument Reliability: n/a 
Total PTSD symptoms 
Observed Correlation: .52 Sample Size: 18    Measurement Time: 3m 
Measurement Instrument: CAPS  Measurement Type: 1 
Instrument Reliability: n/a 
Re-experiencing PTSD symptoms 
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Observed Correlation: n/a Sample Size:     Measurement Time:  
Measurement Instrument:   Measurement Type:  
Instrument Reliability:  
Hyperarousal PTSD symptoms 
Observed Correlation: n/a Sample Size:     Measurement Time:  
Measurement Instrument:   Measurement Type:  
Instrument Reliability:  
Avoidance PTSD symptoms 
Observed Correlation: n/a Sample Size:     Measurement Time:  
Measurement Instrument:   Measurement Type:  
Instrument Reliability:  
SUD alcohol symptoms 
Observed Correlation: .61 Sample Size: 18    Measurement Time: 3m 
Measurement Instrument: ASI ETOH Measurement Type: 1 
Instrument Reliability: n/a 
SUD drug symptoms 
Observed Correlation: .78 Sample Size: 18     Measurement Time: 3m 
Measurement Instrument: ATI drug  Measurement Type: 1 
Instrument Reliability: n/a 
Other symptoms 
Observed Correlation: n/a  Sample Size:     Measurement Time:  
Measurement Instrument:   Measurement Type:  
Instrument Reliability:  What measured:    
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Article Information 
Article ID: 35  Title: Comorbid posttraumatic stress disorder and substance use 
disorders: treatment outcomes and the role of coping 
Authors: Brown, P. J., Read, J. P., Kahler, C. W. Type of article: 2  Date:  2003 
Treatment (Independent Variable)  
Type of Treatment: 2  Treatment Subtype: ip Exposure: 0 
Treatment Dosage: n/a  Weekly Dosage:   n/a    
Demographics of Sample 
Age: 37   Female%: 51   Caucasian%: 90   African-American%: n/a  
Asian American%: n/a  Latino%: n/a  American Indian%: n/a  Other%: n/a 
%Vets: n/a Primary Substance(s): n/a 
SUD Type: n/a    Trauma Type: various Dropout%: 10 
Outcomes (Dependent Variable)  
Total PTSD symptoms 
Observed Correlation: .46 Sample Size: 55    Measurement Time: 6m 
Measurement Instrument: CAPS  Measurement Type: 1 
Instrument Reliability: n/a 
Re-experiencing PTSD symptoms 
Observed Correlation: n/a Sample Size:     Measurement Time:  
Measurement Instrument:   Measurement Type:  
Instrument Reliability:  
Hyperarousal PTSD symptoms 
Observed Correlation: n/a Sample Size:     Measurement Time:  
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Measurement Instrument:   Measurement Type:  
Instrument Reliability:  
Avoidance PTSD symptoms 
Observed Correlation: n/a Sample Size:     Measurement Time:  
Measurement Instrument:   Measurement Type:  
Instrument Reliability:  
SUD alcohol symptoms 
Observed Correlation: .56 Sample Size: 55    Measurement Time: 6m 
Measurement Instrument: TLFB   Measurement Type: 1 
Instrument Reliability: n/a 
SUD drug symptoms 
Observed Correlation: .56 Sample Size: 55    Measurement Time: 6m 
Measurement Instrument: TLFB   Measurement Type: 1 
Instrument Reliability: n/a 
Other symptoms 
Observed Correlation: .30 Sample Size: 55     Measurement Time: 6m 
Measurement Instrument: SC-90   Measurement Type: 1 
Instrument Reliability: n/a What measured:   general psych symptoms 
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Article Information 
Article ID: 36   Title: A pilot study of seeking safety with OEF/OIF veterans 
Authors: Norman, S. B., Wilkins, K. C., Tapert, S. F., Lang, A. J., Najavits, L. M.  
Type of article: 3  Date:  2010 
Treatment (Independent Variable)  
Type of Treatment: 1   Treatment Subtype: Seeking Safety   Exposure: 0 
Treatment Dosage: 10w  Weekly Dosage:  1.5h     
Demographics of Sample 
Age: 32.11     Female%: 0     Caucasian%: 66.7   African-American%: 22.2 
Asian American%: 0  Latino%: 0  American Indian%: 0  Other%: 11.11 
%Vets: 100  Primary Substance(s): 77.8 ETOH, 22.2 cannibis 
SUD Type: n/a    Trauma Type: n/a  Dropout%: 36 
Outcomes (Dependent Variable)  
Total PTSD symptoms 
Observed Correlation: .31 Sample Size: 9     Measurement Time: post 
Measurement Instrument: PCL-military  Measurement Type: 1 
Instrument Reliability: n/a 
Total PTSD symptoms 
Observed Correlation: .75 Sample Size: 4     Measurement Time: 3m 
Measurement Instrument: PCL-military  Measurement Type: 1 
Instrument Reliability: n/a 
Total PTSD symptoms 
Observed Correlation: .55 Sample Size: 4     Measurement Time: 6m 
Treatment of Dual Diagnosis 150 
 
 
Measurement Instrument: PCL-military  Measurement Type: 1 
Instrument Reliability: n/a 
Re-experiencing PTSD symptoms 
Observed Correlation: n/a Sample Size:     Measurement Time:  
Measurement Instrument:   Measurement Type:  
Instrument Reliability:  
Hyperarousal PTSD symptoms 
Observed Correlation: n/a Sample Size:     Measurement Time:  
Measurement Instrument:   Measurement Type:  
Instrument Reliability:  
Avoidance PTSD symptoms 
Observed Correlation: n/a Sample Size:     Measurement Time:  
Measurement Instrument:   Measurement Type:  
Instrument Reliability:  
SUD alcohol symptoms 
Observed Correlation: .22 Sample Size: 9    Measurement Time: post 
Measurement Instrument: AUDIT  Measurement Type: 1 
Instrument Reliability: n/a 
SUD alcohol symptoms 
Observed Correlation: .49 Sample Size: 4    Measurement Time: 3m 
Measurement Instrument: AUDIT  Measurement Type: 1 
Instrument Reliability: n/a 
SUD alcohol symptoms 
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Observed Correlation: .55 Sample Size: 4    Measurement Time: 6m 
Measurement Instrument: AUDIT  Measurement Type: 1 
Instrument Reliability: n/a 
SUD drug symptoms 
Observed Correlation: n/a Sample Size:     Measurement Time:  
Measurement Instrument:   Measurement Type:  
Instrument Reliability: 
Other symptoms 
Observed Correlation: .41 Sample Size: 9    Measurement Time: post 
Measurement Instrument: BDI-II  Measurement Type: 1 
Instrument Reliability:  n/a What measured:   depression 
 Other symptoms 
Observed Correlation: .74 Sample Size: 4    Measurement Time: 3m 
Measurement Instrument: BDI-II  Measurement Type: 1 
Instrument Reliability:  n/a What measured:   depression 
Other symptoms 
Observed Correlation: .19 Sample Size: 4    Measurement Time: 6m 
Measurement Instrument: BDI-II  Measurement Type: 1 
Instrument Reliability:  n/a What measured:   depression 
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Appendix B: Coding Definitions 
Article Information 
Article ID: Unique 3 digit number used to identify study. Will start at 001 and increase 
with each study 
 
Title: Title of article 
 
Authors: Authors of article 
 
Type of Article: Single digit code defined as follows: Peer-reviewed journal = 1; Book 
chapter = 2; Technical/research report = 3; Presentation = 4; Dissertation = 5; Thesis = 6; 
Other = 7 
 
Date: Publication or presentation year 
 
Treatment (Independent Variable) 
 
Type of Treatment: Single digit code defined as follows: Integrated treatment = 1; Non-
integrated treatment SUD focused = 2; Non-integrated treatment PTSD focused = 3; 
Non-integrated treatment Other = 4; No-treatment Control = 5 
 
Treatment Subtype: Name of Treatment (e.g. Seeking Safety or CBT) 
 
Exposure: Presence of an exposure based component in treatment: 0 = No exposure; 1 = 
exposure  
 
Treatment Dosage: Number of weeks of treatment 
 
Weekly Dosage: Treatment hours per week 
 
Age: Mean age of sample 
 
<Demographics>%: % of individuals undergoing treatment type in each demographic 
category. 
 
Primary Substance: Primary substance used by participants in study 
 
SUD Type: Abuse or Dependence 
 
Trauma type: type of trauma  - 0 = unknown; 1 = childhood; 2 = military; 3 = accident;   
4 = violence 
 
Dropout %: % of individuals who did not complete treatment for any reason 
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Outcomes (Dependent Variable) 
 
Sample Size: Number of individuals undergoing that treatment 
Measurement Time: Number of weeks after pretest  
 
Observed Correlation: Study observed effect size in r between pre and post tests 
 
Measurement Instrument: Name of instrument 
 
Measurement Type: Single digit code defined as follows: Self-report = 1; Physiological 
measure = 2; Behavioral Observation = 3 
 
Instrument reliability: Reliability of instrument 
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Appendix C: Transformations  (Rosenthal, 1994)* 
t: r=t/√(t2+df) 
F: r=√(F/(F+df)) 
χ
2: r=√(χ2/n) 
z: r=z/√n 
Pre-post difference: d = (m1 – m2)/sd 
p: Consult z-distribution table and set to t 
d: r=d/√(d2+4) 
*Other conversion formulae were used for statistics not listed here. 
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Appendix D: Corrections (Hunter & Schmidt, 2004) 
 
Formulae      Definitions 
Attenuation: rc=r/(√(rxx)* √(ryy))   rc: corrected correlation 
Construct Validity: rc =r/(a1*a2)   r: observed correlation 
50/50 Dichotomization: 
 
rc =r/.8   rxx: dependent variable reliability 
90/10 Dichotomization: 
 
rc =r/.59   ryy: independent variable reliability 
Multiple Measures: rc =∑rxy/√(k+k(k-1) rxx  ) a1 and a2: construct validities 
Range Restriction: rc =((σe/σr)*r)/√(((σe/σr)2-1)r2+1) k: # of intermeasure correlations 
Correlation Bias: rc =r/((2N-3)/(2N-2)) rxx  : average of off-diagonal 
correlations between measures 
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Appendix E: Basic Meta-analysis formulae (Hunter & Schmidt, 2004) 
Formulae      Definitions 
r  = ∑(Niri)/∑Ni *     r  : Corrected mean correlation 
σr
2 
= ∑(Ni(ri- r  )2)/∑Ni *    Ni: Study sample size 
σe
2 
= (1- r  2)2/( N  - 1)    ri: Observed study correlation 
N  =N/K      σr2: Observed variance 
σp
2 = 
σr
2 
- σe
2      
σe
2: Expected variance 
Rel(r) = σe2/σr2      N: Total sample size 
*Substitute NiAi for Ni  and rc for ri   K: Number of studies 
to weight by error 
       N  : Average sample size 
x=K( r  / r  c -1) 
       σp
2: Corrected variance 
 
Rel(r): Reliability of study 
correlations 
 
Ai: Attenuation factor (denominators 
of corrections + Range restriction 
formula (p. 122)) 
 
r  c: Critical value for the 
correlation 
 
x: Number of studies averaging null 
results needed to bring the observed 
correlation down to the critical value 
 
 
